{"questions": [{"body": "Which oncogene somatic mutations are associated to in situ carcinoma evolution from colonic polyp adenomas?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35173208"], "ideal_answer": "The oncogene somatic mutations associated with in situ carcinoma evolution from colonic polyp adenomas include APC, KRAS, and TP53 mutations, with frequencies slightly lower in adenoma samples compared to in situ carcinoma samples.", "exact_answer": [["APC"], ["KRAS"], ["TP53"]], "type": "list", "id": "65f772d3c4010b4d78000022", "snippets": [{"offsetInBeginSection": 835, "offsetInEndSection": 952, "text": "The APC, KRAS and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35173208", "endSection": "abstract"}, {"offsetInBeginSection": 472, "offsetInEndSection": 543, "text": "APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35173208", "endSection": "abstract"}, {"offsetInBeginSection": 1120, "offsetInEndSection": 1197, "text": "APC gene 42.9-56.0-54.5%; KRAS gene 32.7-32.0-45.5%; TP53 gene 8.2-20.0-18.2%", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35173208", "endSection": "abstract"}]}, {"body": "What medications were tested in the COSMIC-313 trial?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36239611", "http://www.ncbi.nlm.nih.gov/pubmed/37062953", "http://www.ncbi.nlm.nih.gov/pubmed/37246571", "http://www.ncbi.nlm.nih.gov/pubmed/37163623"], "ideal_answer": "The medications tested in the COSMIC-313 trial were cabozantinib, nivolumab, and ipilimumab.", "exact_answer": [["cabozantinib"], ["nivolumab"], ["ipilimumab"]], "type": "list", "id": "65d140e71930410b1300003f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 257, "text": "The COSMIC-313 phase 3 randomized controlled trial tested the triplet combination of cabozantinib with nivolumab and ipilimumab in comparison with nivolumab plus ipilimumab control as fist-line systemic therapy in metastatic clear cell renal cell carcinoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36239611", "endSection": "abstract"}, {"offsetInBeginSection": 422, "offsetInEndSection": 651, "text": "A recently conducted trial (COSMIC-313) showed superior efficacy with a triplet combination of cabozantinib, nivolumab, and ipilimumab when compared to a placebo, nivolumab, and ipilimumab but at the cost of additional toxicity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37062953", "endSection": "abstract"}, {"offsetInBeginSection": 697, "offsetInEndSection": 1074, "text": "As concern the triplet therapy (i.e. nivolumab+ipilumumab+cabozantinib), the updated analysis of the COSMIC-313 study confirmed a significant PFS advantage in the subgroup of mRCC patients at intermediate IMDC risk, while the lack of benefit in the poor risk group supports the critical role of immunotherapy (but not of VEGFR-TKIs) in this poor prognosis subgroup of patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37246571", "endSection": "abstract"}, {"offsetInBeginSection": 2009, "offsetInEndSection": 2480, "text": "CONCLUSIONS: Among patients with previously untreated, advanced renal-cell carcinoma who had intermediate or poor prognostic risk, treatment with cabozantinib plus nivolumab and ipilimumab resulted in significantly longer progression-free survival than treatment with nivolumab and ipilimumab alone. Grade 3 or 4 adverse events were more common in the experimental group than in the control group. (Funded by Exelixis; COSMIC-313 ClinicalTrials.gov number, NCT03937219.).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37163623", "endSection": "abstract"}]}, {"body": "What is the most common surgical treatment for hydrocephalus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37402676", "http://www.ncbi.nlm.nih.gov/pubmed/34152450"], "ideal_answer": "The most common surgical treatment for hydrocephalus is the insertion of a ventriculoperitoneal (VP) shunt. This procedure involves placing a catheter in the ventricles of the brain to drain excess cerebrospinal fluid (CSF) into the peritoneal cavity, where it can be absorbed by the body.", "exact_answer": [["The most common surgical treatment for hydrocephalus is shunt surgery."]], "type": "factoid", "id": "65f85ec7c4010b4d78000052", "snippets": [{"offsetInBeginSection": 207, "offsetInEndSection": 360, "text": "Gravitation-assisted shunt valves are designed to prevent hydrostatic over-drainage frequently observed in the long course of shunt-treated hydrocephalus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34152450", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 205, "text": "Shunt treatment for hydrocephalus in children should aim for sustainable flexibility in regard to optional, perspective pressure level adjustment during advancing physical and mental development", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34152450", "endSection": "abstract"}, {"offsetInBeginSection": 637, "offsetInEndSection": 741, "text": "hydrocephalic neonates and infants who received initial VP-shunt insertion in the early post-natal phase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34152450", "endSection": "abstract"}, {"offsetInBeginSection": 1424, "offsetInEndSection": 1477, "text": "primary VP-shunt insertion at a mean age of 10 weeks ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34152450", "endSection": "abstract"}, {"offsetInBeginSection": 947, "offsetInEndSection": 1057, "text": "Shunt surgery is preferred for secondary hydrocephalus, especially for secondary normal pressure hydrocephalus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37402676", "endSection": "abstract"}]}, {"body": "Explain the difference between eosinophilic esophagitis and reflux-induced esophagitis.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37456790", "http://www.ncbi.nlm.nih.gov/pubmed/37814560", "http://www.ncbi.nlm.nih.gov/pubmed/37456973", "http://www.ncbi.nlm.nih.gov/pubmed/37231862", "http://www.ncbi.nlm.nih.gov/pubmed/36840634", "http://www.ncbi.nlm.nih.gov/pubmed/36351516", "http://www.ncbi.nlm.nih.gov/pubmed/37064719"], "ideal_answer": "Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease characterized by eosinophilic infiltration and inflammation of the esophagus, often triggered by exposure to dietary or environmental antigens. Reflux-induced esophagitis, also known as gastroesophageal reflux disease (GERD), is a condition in which acid from the stomach enters the esophagus, leading to inflammation and damage to the esophageal lining. While both conditions can cause esophageal dysfunction, EoE is primarily driven by an immune response to antigens, whereas GERD is caused by the reflux of stomach acid into the esophagus.", "type": "summary", "id": "65f1d021c4010b4d78000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease characterized by eosinophilic infiltration, leading to esophageal dysfunction, inflammation, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37456790", "endSection": "abstract"}, {"offsetInBeginSection": 334, "offsetInEndSection": 557, "text": "asal cell hyperplasia may occur in patients with gastroesophageal reflux disease (GERD), a condition in which acid from the stomach enters the esophagus, or eosinophilic esophagitis (EoE), an emerging form of food allergy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37064719", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "Eosinophilic esophagitis (EoE) is a chronic and progressive immune-mediated disease of the esophagus associated with antigen-driven type 2 inflammation and symptoms of esophageal dysfunction", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36351516", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 290, "text": "Eosinophilic esophagitis (EoE) is an inflammatory condition of the esophagus that is quickly becoming a more recognized cause of esophageal dysfunction and dysphagia. The cause of EoE is thought to be due to an inflammatory response triggered by exposure to dietary or environmental antigen", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36840634", "endSection": "abstract"}, {"offsetInBeginSection": 13, "offsetInEndSection": 220, "text": " There is a complex interrelationship between gastroesophageal reflux disease (GERD) and eosinophilic esophagitis (EoE) potentially promoting the occurrence and modulating severity of each other reciprocally", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37231862", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 297, "text": "Eosinophilic esophagitis (EoE) is a chronic eosinophil inflammation that seems to be T helper type 2 antigen-driven. The disease is one of several eosinophilic gastrointestinal disorders in which there appears to be inflammation of the gastrointestinal tract without any apparent underlying causes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37456973", "endSection": "abstract"}, {"offsetInBeginSection": 27, "offsetInEndSection": 232, "text": "Eosinophilic esophagitis (EoE) is a food allergen-induced disease of the esophagus. Chronic, eosinophil-predominant inflammation eventually leads to fibrosis, esophageal dysfunction and severe morbidity. S", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37814560", "endSection": "abstract"}]}, {"body": "Should men be immunized against Human Papilloma Virus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36691362", "http://www.ncbi.nlm.nih.gov/pubmed/36305982", "http://www.ncbi.nlm.nih.gov/pubmed/37264392"], "ideal_answer": "Yes, men should be immunized against Human Papilloma Virus (HPV). HPV is known to contribute to male cancers of the mouth, throat, anus, and penis, as well as causing genital warts. The HPV vaccine is one of the most effective public health measures for preventing HPV-related cancers and other diseases.", "type": "summary", "id": "65f8611dc4010b4d78000055", "snippets": [{"offsetInBeginSection": 384, "offsetInEndSection": 518, "text": "As scientific knowledge of HPV-related cancers has advanced, it has become evident that HPV vaccination is a priority for both genders", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36691362", "endSection": "abstract"}, {"offsetInBeginSection": 520, "offsetInEndSection": 634, "text": "HPV is known to contribute to male cancers of the mouth, throat, anus, and penis, as well as causing genital warts", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36691362", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "The human papillomavirus (HPV) vaccine is one of the most effective public health measures for preventing HPV-related cancers and other diseases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36305982", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 107, "text": "Almost all cases of cervical and anal cancer have been linked to the human papillomavirus (HPV)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37264392", "endSection": "abstract"}, {"offsetInBeginSection": 180, "offsetInEndSection": 291, "text": "both men and women can also develop cancers of the anus, oral cavity, and oropharynx that are attributed to HPV", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37264392", "endSection": "abstract"}]}, {"body": "What is the target of Selpercatinib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36729098", "http://www.ncbi.nlm.nih.gov/pubmed/36568522", "http://www.ncbi.nlm.nih.gov/pubmed/36572992", "http://www.ncbi.nlm.nih.gov/pubmed/36626081", "http://www.ncbi.nlm.nih.gov/pubmed/36632846", "http://www.ncbi.nlm.nih.gov/pubmed/36422787", "http://www.ncbi.nlm.nih.gov/pubmed/36416226"], "ideal_answer": "Selpercatinib is a selective inhibitor of rearranged during transfection (RET) kinase.", "exact_answer": [["Selpercatinib targets the rearranged during transfection (RET) kinase."]], "type": "factoid", "id": "65cfa22b1930410b1300000c", "snippets": [{"offsetInBeginSection": 359, "offsetInEndSection": 486, "text": "More recently, two selective RET inhibitors, selpercatinib and pralsetinib, demonstrated higher efficacy and good tolerability.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36729098", "endSection": "abstract"}, {"offsetInBeginSection": 1515, "offsetInEndSection": 1641, "text": "Drug exposure of RET inhibitors is expected to increase with CYP 3A4 inhibition, with selpercatinib being the least affected. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36568522", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572992", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "OBJECTIVE: Selpercatinib and pralsetinib are new targeted therapies used to treat patients with non-small cell lung cancer (NSCLC) due to RET gene rearrangements.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572992", "endSection": "abstract"}, {"offsetInBeginSection": 1606, "offsetInEndSection": 1671, "text": "Three RET-mutant patients received selpercatinib; all showed PR. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36626081", "endSection": "abstract"}, {"offsetInBeginSection": 828, "offsetInEndSection": 981, "text": "Rapid translation and regulatory approval of selective RET inhibitors, selpercatinib and pralsetinib, have opened up the field of RET precision oncology.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36632846", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36422787", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 223, "text": "Selpercatinib (Retevmo\u00ae/Retsevmo\u00ae) is an orally-administered, selective inhibitor of rearranged during transfection (RET) kinase approved for the treatment of advanced RET fusion-positive non-small cell lung cancer (NSCLC).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36422787", "endSection": "abstract"}, {"offsetInBeginSection": 927, "offsetInEndSection": 1090, "text": "Thus, currently available evidence suggests that selpercatinib is a promising new RET-targeted therapy option for patients with advanced RET fusion-positive NSCLC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36422787", "endSection": "abstract"}, {"offsetInBeginSection": 74, "offsetInEndSection": 169, "text": "Selpercatinib is a highly selective RET inhibitor for treatment of metastatic RET-altered MTC. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36416226", "endSection": "abstract"}]}, {"body": "What are the most commonly used pain scales for the measurement of pain in ICU?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35656052", "http://www.ncbi.nlm.nih.gov/pubmed/32389396", "http://www.ncbi.nlm.nih.gov/pubmed/30834018", "http://www.ncbi.nlm.nih.gov/pubmed/28362033", "http://www.ncbi.nlm.nih.gov/pubmed/27833752", "http://www.ncbi.nlm.nih.gov/pubmed/30820228"], "ideal_answer": "The most commonly used pain scales for the measurement of pain in the ICU are the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT). These scales have been validated and shown to have good validity and reliability in assessing pain in nonverbal and mechanically ventilated ICU patients.", "exact_answer": [["Behavioral Pain Scale (BPS)"], ["Critical Care Pain Observation Tool (CPOT)"]], "type": "list", "id": "644108b157b1c7a315000053", "snippets": [{"offsetInBeginSection": 99, "offsetInEndSection": 280, "text": "This study aims to compare the diagnostic value of the critical-care pain observation tool (CPOT) and the behavioral pain scale (BPS) for pain assessment among unconscious patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35656052", "endSection": "abstract"}, {"offsetInBeginSection": 1319, "offsetInEndSection": 1579, "text": " CPOT and BPS have acceptable discriminant validity in differentiating nonnociceptive and nociceptive procedural pain although the effect size of CPOT is larger than that of BPS. Although both instruments have low reliability, the reliability of BPS is better.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35656052", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 216, "text": " To determine the concordance of Zurich Observation Pain Assessment (ZOPA) with the behavioural Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT) to detect pain in nonverbal ICU patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32389396", "endSection": "abstract"}, {"offsetInBeginSection": 1232, "offsetInEndSection": 1350, "text": "ZOPA is concordant with the BPS and the CPOT to indicate pain but detects pain earlier due to the low threshold value.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32389396", "endSection": "abstract"}, {"offsetInBeginSection": 1563, "offsetInEndSection": 1770, "text": "Based on available evidence and investigations, CPOT and BPS tools have good validity and reliability to be used in pain assessment in Nonverbal Intubated Critically Adult Patients after Open-Heart Surgery. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30834018", "endSection": "abstract"}, {"offsetInBeginSection": 1073, "offsetInEndSection": 1258, "text": "Current research shows that the two tools best validated for patients unable to self-report pain are the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28362033", "endSection": "abstract"}, {"offsetInBeginSection": 2040, "offsetInEndSection": 2199, "text": "In critically ill mechanically ventilated patients, both CPOT and BPS can be used for assessment of pain intensity with different sensitivity and specificity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27833752", "endSection": "abstract"}, {"offsetInBeginSection": 1464, "offsetInEndSection": 1651, "text": "Critically ill patients in ICU experience a different range of pain in routine daily care. BPS and CPOT scales could be used successfully for monitoring of pain in this group of patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30820228", "endSection": "abstract"}]}, {"body": "Can Ultrasonography be used to detect tumors in dogs and cats?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36790748", "http://www.ncbi.nlm.nih.gov/pubmed/15005361", "http://www.ncbi.nlm.nih.gov/pubmed/7591927"], "ideal_answer": "Yes, ultrasonography can be used to detect tumors in dogs and cats. It is considered a useful tool for determining the extent of disease in small-animal patients with mast cell tumors when used in conjunction with histopathology or cytology. In cases of intradural masses, intraoperative ultrasonography can help delineate the extent of the tumor.", "exact_answer": "yes", "type": "yesno", "id": "65f5a3efc4010b4d78000017", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Ultrasonography (US) and computed\u00a0tomography\u00a0(CT) are used to diagnose neoplastic and non-neoplastic focal renal lesions\u00a0in\u00a0dogs\u00a0and\u00a0cats", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36790748", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 246, "text": "A retrospective survey from January 1989 to January 1999 of Tufts University Foster Hospital for Small Animals radiology records of 12 dogs and seven cats with cytologically or histopathologically confirmed abdominal mast cell disease was perform", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15005361", "endSection": "abstract"}, {"offsetInBeginSection": 1257, "offsetInEndSection": 1520, "text": "Although these findings are not specific to the disease in either species, abdominal ultrasound is considered a useful tool for determining the extent of disease in small-animal patients with mast cell tumor if used in conjunction with histopathology or cytology.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15005361", "endSection": "abstract"}, {"offsetInBeginSection": 937, "offsetInEndSection": 1050, "text": "In the 2 dogs with intradural masses, intraoperative ultrasonography helped to delineate the extent of the tumor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7591927", "endSection": "abstract"}]}, {"body": "Can Antioxidant curcumin kill tumor cells?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37191314", "http://www.ncbi.nlm.nih.gov/pubmed/36986483", "http://www.ncbi.nlm.nih.gov/pubmed/37333486", "http://www.ncbi.nlm.nih.gov/pubmed/37210578"], "ideal_answer": "Curcumin, an antioxidant compound found in turmeric, has been shown to have anti-tumor effects and can induce apoptosis (cell death) in various types of cancer cells, including colon cancer, hepatocellular carcinoma, and colorectal cancer. It achieves this by regulating specific signaling pathways involved in tumor growth and survival, such as STAT3/VEGF/HIF-1\u03b1 signaling. Additionally, curcumin can activate ferroptosis, a form of cell death that is dependent on iron and lipid peroxidation. These findings suggest that curcumin has the potential to kill tumor cells through multiple mechanisms.", "exact_answer": "yes", "type": "yesno", "id": "65f1dadac4010b4d78000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Curcumin inhibits colon cancer malignant progression and promotes T cell killing by regulating miR-206 expression", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37191314", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "Curcumin and Andrographis Exhibit Anti-Tumor Effects in Colorectal Cancer via Activation of Ferroptosis and Dual Suppression of Glutathione Peroxidase-4 and Ferroptosis Suppressor Protein-1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36986483", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Curcumin induces apoptosis in human hepatocellular carcinoma cells by decreasing the expression of STAT3/VEGF/HIF-1\u03b1 signaling.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37333486", "endSection": "title"}]}, {"body": "What medication were tested in the PEMMELA trial?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37844598"], "ideal_answer": "The PEMMELA trial tested the combination of pembrolizumab and lenvatinib in second-line and third-line patients with pleural mesothelioma.", "exact_answer": [["Pembrolizumab"], ["Lenvatinib"]], "type": "list", "id": "65d373e21930410b13000049", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37844598", "endSection": "title"}]}, {"body": "Please summarize MuSK Antibody positive Myasthenia Gravis.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36396811", "http://www.ncbi.nlm.nih.gov/pubmed/37455510", "http://www.ncbi.nlm.nih.gov/pubmed/36527328", "http://www.ncbi.nlm.nih.gov/pubmed/37150596", "http://www.ncbi.nlm.nih.gov/pubmed/37564637"], "ideal_answer": "MuSK Antibody positive Myasthenia Gravis (MG) is a subtype of MG that is predominantly seen in women of childbearing age. It is characterized by focal muscle weakness in the neck, facial, and bulbar muscles, along with fatigability. The pathogenic antibodies in MuSK MG belong to the immunoglobulin subclass (Ig)G4, which contributes to their specific properties and pathogenic profile.", "type": "summary", "id": "65f70915c4010b4d7800001a", "snippets": [{"offsetInBeginSection": 102, "offsetInEndSection": 338, "text": "for anti-muscle specific tyrosine kinase (MuSK) antibody (Ab) in a large cohort of anti-acetylcholine receptor (AChR) Ab-negative generalized myasthenia gravis (MG), and also to investigate clinical contexts for the diagnosis of MuSK MG", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36396811", "endSection": "abstract"}, {"offsetInBeginSection": 334, "offsetInEndSection": 558, "text": "We compared the plasma concentrations of 15 myokines in 63 patients with acetylcholine receptor antibody (Ab)-positive MG and 14 with muscle-specific tyrosine kinase Ab-positive MG (MuSK MG) with those in 15 healthy controls", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37455510", "endSection": "abstract"}, {"offsetInBeginSection": 296, "offsetInEndSection": 378, "text": "In this report, we describe three patients with anti-muscle-specific kinase (MuSK)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36527328", "endSection": "abstract"}, {"offsetInBeginSection": 18, "offsetInEndSection": 155, "text": " Myasthenia gravis (MG) with muscle-specific tyrosine kinase (MuSK) antibodies (MMG) is predominantly seen in women of childbearing age. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37150596", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 372, "text": "Muscle-specific kinase (MuSK) Myasthenia Gravis (MG) represents a prototypical antibody-mediated disease characterized by predominantly focal muscle weakness (neck, facial, and bulbar muscles) and fatigability. The pathogenic antibodies mostly belong to the immunoglobulin subclass (Ig)G4, a feature which attributes them their specific properties and pathogenic profile. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37564637", "endSection": "abstract"}]}, {"body": "What proportion of risk is attributable to obesity in colorectal cancer women development?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17823417", "http://www.ncbi.nlm.nih.gov/pubmed/37264099"], "ideal_answer": "In women, obesity is associated with a 16% increased risk of developing colorectal cancer. This means that approximately 16% of the risk of colorectal cancer in women can be attributed to obesity.", "exact_answer": [["The proportion of risk attributable to obesity in colorectal cancer development in women is 4% (hazard ratio = 1.04 [1.01-1.18], P = 0.001)."]], "type": "factoid", "id": "65f7728fc4010b4d78000021", "snippets": [{"offsetInBeginSection": 1166, "offsetInEndSection": 1586, "text": "Colon cancer risk increased with increasing waist circumference (per 10-cm increase) in both men (RR: 1.33; 95% CI: 1.19, 1.49) and women (RR: 1.16; 95% CI: 1.09, 1.23) and with increasing waist-hip ratio (per 0.1-unit increase) in both men (RR: 1.43; 95% CI: 1.19, 1.71) and women (RR: 1.20; 95% CI: 1.08, 1.33).CONCLUSIONS: The association between obesity and colon and rectal cancer risk varies by sex and cancer site", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17823417", "endSection": "abstract"}, {"offsetInBeginSection": 999, "offsetInEndSection": 1177, "text": " The men in the obese/obese group had a higher risk of colon cancer than women (hazard ratio\u2009=\u20091.13 [1.10-1.17] in men, and hazard ratio\u2009=\u20091.04 [1.01-1.18] in women, P\u2009=\u20090.001). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37264099", "endSection": "abstract"}]}, {"body": "What is the mechanisms of action of Sotorasib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36690705", "http://www.ncbi.nlm.nih.gov/pubmed/36563789", "http://www.ncbi.nlm.nih.gov/pubmed/36566134", "http://www.ncbi.nlm.nih.gov/pubmed/36764316", "http://www.ncbi.nlm.nih.gov/pubmed/36581205", "http://www.ncbi.nlm.nih.gov/pubmed/36577165"], "ideal_answer": "Sotorasib is a small molecule inhibitor of the GTPase protein KRAS p.G12C. It specifically and irreversibly inhibits the activity of KRAS p.G12C mutation, which is involved in non-small cell lung cancer (NSCLC).", "type": "summary", "id": "65ce88be1930410b13000002", "snippets": [{"offsetInBeginSection": 467, "offsetInEndSection": 582, "text": "At progression, the patient continued entrectinib and started sotorasib, a small molecule inhibitor of KRAS p.G12C.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36690705", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1218, "text": "Patients with metastatic NSCLC bearing a ROS1 gene fusion usually experience prolonged disease control with ROS1-targeting tyrosine kinase inhibitors (TKI), but significant clinical heterogeneity exists in part due to the presence of co-occurring genomic alterations. Here, we report on a patient with metastatic NSCLC with a concurrent ROS1 fusion and KRAS p.G12C mutation at diagnosis who experienced a short duration of disease control on entrectinib, a ROS1 TKI. At progression, the patient continued entrectinib and started sotorasib, a small molecule inhibitor of KRAS p.G12C. A patient-derived cell line generated at progression on entrectinib demonstrated improved TKI responsiveness when treated with entrectinib and sotorasib. Cell-line growth dependence on both ROS1 and KRAS p.G12C was further reflected in the distinct downstream signaling pathways activated by each driver. Clinical benefit was not observed with combined therapy of entrectinib and sotorasib possibly related to an evolving KRAS p.G12C amplification identified on repeated molecular testing. This case supports the need for broad molecular profiling in patients with metastatic NSCLC for potential therapeutic and prognostic information.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36690705", "endSection": "abstract"}, {"offsetInBeginSection": 198, "offsetInEndSection": 481, "text": "ecent breakthroughs in the development of mutant-specific KRAS inhibitors include the FDA approved drug Lumakras (Sotorasib, AMG510) for KRAS G12C-mutated non-small cell lung cancer (NSCLC), and MRTX1133, a promising clinical candidate for the treatment of KRAS G12D-mutated cancers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36563789", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "[Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36566134", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "Following the CodeBreak 100 study, since 2021 sotorasib has been available in France, with authorization for early access in treatment of non-small cell lung cancer with a KRAS G12C mutation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36566134", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 315, "text": "BACKGROUND: Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRASG12C. We compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRASG12C mutation who had been previously treated with other anticancer drugs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36764316", "endSection": "abstract"}, {"offsetInBeginSection": 639, "offsetInEndSection": 802, "text": "This discovery stemmed from our finding that Survivin expression is downregulated upon treatment of pancreatic cancer cells with the KRASG12C inhibitor Sotorasib. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36581205", "endSection": "abstract"}, {"offsetInBeginSection": 96, "offsetInEndSection": 258, "text": "Sotorasib was the first-in-class KRAS inhibitor to reach the US and European market, and its pharmacological inhibition is restricted to the KRAS p.G12C mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36577165", "endSection": "abstract"}]}, {"body": "What is a spillover event?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37367190", "http://www.ncbi.nlm.nih.gov/pubmed/37672628"], "ideal_answer": "A spillover event refers to the transmission of a pathogen from its natural reservoir host to a new host species, such as humans. In the context of zoonotic diseases, a spillover event occurs when a pathogen jumps from animals to humans, leading to human infections and potential outbreaks.", "type": "summary", "id": "65f843cbc4010b4d78000042", "snippets": [{"offsetInBeginSection": 994, "offsetInEndSection": 1166, "text": "importance of assessing the zoonotic potential of widely distributed batborne CoV in order to monitor changes in genomic composition of viruses and prevent spillover events", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367190", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 420, "text": "Japanese encephalitis virus (JEV) is a mosquito-borne zoonotic flavivirus and the leading cause of pediatric encephalitis in the Asian Pacific region. The transmission cycle primarily involves Culex spp. mosquitoes and Ardeid birds, with domestic pigs (Sus scrofa domestica) being the source of infectious viruses for the spillover of JEV from the natural endemic transmission cycle into the human population", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672628", "endSection": "abstract"}]}, {"body": "Cilta-cel was developed for treatment of which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36411210", "http://www.ncbi.nlm.nih.gov/pubmed/36271807", "http://www.ncbi.nlm.nih.gov/pubmed/36269898", "http://www.ncbi.nlm.nih.gov/pubmed/37497629"], "ideal_answer": "Cilta-cel was developed for the treatment of relapsed or refractory multiple myeloma (RRMM).", "exact_answer": [["Cilta-cel was developed for the treatment of relapsed or refractory multiple myeloma (RRMM)."]], "type": "factoid", "id": "65cfd4b21930410b13000020", "snippets": [{"offsetInBeginSection": 1174, "offsetInEndSection": 1407, "text": " Additional indirect treatment comparisons conducted separately for ide-cel and cilta-cel have demonstrated that these CAR-T therapies hold promise for substantial clinical benefit relative to currently available treatments for RRMM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36411210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 607, "text": "OBJECTIVE: This study used the latest available data cuts from the CARTITUDE-1 and KarMMa clinical trials to update previously published matching-adjusted indirect treatment comparisons (MAICs) assessing the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus the FDA-approved idecabtagene vicleucel (ide-cel) dose range of 300 to 450\u2009\u00d7\u2009106 CAR-positive T-cells in the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who were previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody (i.e. triple-class exposed)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36271807", "endSection": "abstract"}, {"offsetInBeginSection": 1645, "offsetInEndSection": 1850, "text": "CONCLUSIONS: These analyses demonstrate improved efficacy with cilta-cel versus ide-cel for all outcomes over longer follow-up and highlight its therapeutic potential in triple-class exposed RRMM patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36271807", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 253, "text": "PURPOSE: CARTIFAN-1 aimed to evaluate the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (RRMM).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36269898", "endSection": "abstract"}, {"offsetInBeginSection": 1776, "offsetInEndSection": 1978, "text": "CONCLUSION: These data demonstrate a favorable risk-benefit profile for a single infusion of cilta-cel, resulting in early, deep, and durable responses in heavily pretreated patients with RRMM in China.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36269898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37497629", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 323, "text": "Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma, was approved in USA on 28 February 2022, for patients with relapsed or refractory disease who have received \u22654 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37497629", "endSection": "abstract"}]}, {"body": "Is peritoneal dialysis the best option for infants with kidney failure?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36449100", "http://www.ncbi.nlm.nih.gov/pubmed/32063210"], "ideal_answer": "Peritoneal dialysis (PD) is often considered the best option for infants with kidney failure. PD is a form of dialysis that uses the peritoneal membrane in the abdomen as a natural filter to remove waste products and excess fluid from the body. It is particularly well-suited for infants because it can be performed at home, allowing for more frequent and gentle dialysis treatments. PD also provides better preservation of residual kidney function and allows for growth and development. However, the choice of dialysis modality should be individualized based on the specific needs and circumstances of each infant, and consultation with a pediatric nephrologist is essential.", "exact_answer": "yes", "type": "yesno", "id": "65f86e06c4010b4d7800005a", "snippets": [{"offsetInBeginSection": 48, "offsetInEndSection": 83, "text": "automated peritoneal dialysis (APD)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36449100", "endSection": "abstract"}, {"offsetInBeginSection": 1703, "offsetInEndSection": 1706, "text": "APD", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36449100", "endSection": "abstract"}, {"offsetInBeginSection": 1826, "offsetInEndSection": 1828, "text": "PD", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36449100", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 141, "text": "Peritoneal dialysis (PD) remains the most widely used modality for chronic dialysis in children, particularly in younger children", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32063210", "endSection": "abstract"}]}, {"body": "What should you do if you find an individual that you suspect has overdosed?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33771150", "http://www.ncbi.nlm.nih.gov/pubmed/31420089"], "ideal_answer": "If you find an individual that you suspect has overdosed on opioids, it is important to take immediate action to potentially save their life. The steps to take include: 1) Assess the person's responsiveness and call for emergency medical assistance. 2) If the person is unresponsive and not breathing or breathing abnormally, start performing cardiopulmonary resuscitation (CPR). 3) Administer naloxone if available, following the instructions provided. 4) Stay with the person until medical help arrives, monitoring their breathing and providing any necessary support. It is crucial to seek medical attention even if the person appears to have recovered, as the effects of naloxone may wear off before the opioids in their system. Prompt action and seeking professional help are essential in managing opioid overdose cases.", "exact_answer": [["Assess the situation, check for responsiveness"], ["If the person is unresponsive, call for emergency medical assistance immediately"], ["Place the person in the recovery position to prevent choking on vomit."], ["Perform basic life support measures such as CPR if the person is not breathing."], ["Stay until medical professionals arrive and provide them with the information about the situation."]], "type": "list", "id": "65f85df3c4010b4d78000051", "snippets": [{"offsetInBeginSection": 112, "offsetInEndSection": 462, "text": "The implementation of naloxone programs, such as 'take-home naloxone' (THN), has emerged as a key intervention in reducing opioid overdose deaths. These programs aim to train individuals at risk of witnessing or experiencing an opioid overdose to recognize an opioid overdose and respond with naloxone. Naloxone effectively reverses opioid overdoses ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33771150", "endSection": "abstract"}, {"offsetInBeginSection": 1233, "offsetInEndSection": 1438, "text": "Another medication mode of minimizing risk of overdose is take-home naloxone. Naloxone is an opioid antagonist used to reverse opioid overdose, and take-home naloxone programs aim to prevent fatal overdose", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31420089", "endSection": "abstract"}]}, {"body": "Is Upadacitinib effective for Crohn\u2019s Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36272109", "http://www.ncbi.nlm.nih.gov/pubmed/36968986", "http://www.ncbi.nlm.nih.gov/pubmed/35695972", "http://www.ncbi.nlm.nih.gov/pubmed/31781755"], "ideal_answer": "Yes, Upadacitinib has demonstrated efficacy in treating Crohn's Disease during Phase III clinical trials and real-world data from a tertiary center. It has been shown to induce remission and result in subjective and objective responses in patients with moderate-to-severe Crohn's Disease. Upadacitinib also has a favorable benefit-to-risk profile, even at lower doses.", "exact_answer": "yes", "type": "yesno", "id": "65d126471930410b1300002b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "BACKGROUND: Upadacitinib is a selective Janus kinase inhibitor approved for the management of ulcerative colitis and is under evaluation for the management of Crohn's disease [CD] in Phase 3 clinical trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36272109", "endSection": "abstract"}, {"offsetInBeginSection": 1557, "offsetInEndSection": 1715, "text": "CONCLUSION: In this real-world cohort of highly refractory CD patients, upadacitinib was effective in inducing remission and had an acceptable safety profile.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36272109", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Successful treatment of concomitant alopecia universalis and Crohn's disease with upadacitinib: A case report.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36968986", "endSection": "title"}, {"offsetInBeginSection": 494, "offsetInEndSection": 620, "text": "Upadacitinib, an oral JAK1 inhibitor, has demonstrated efficacy in treating Crohn's disease during phase III clinical trials. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36968986", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Upadacitinib Is Safe and Effective for Crohn's Disease: Real-World Data from a Tertiary Center.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35695972", "endSection": "title"}, {"offsetInBeginSection": 134, "offsetInEndSection": 263, "text": "Phase II trials demonstrated that upadacitinib induces endoscopic remission in patients with moderate-to-severe Crohn's disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35695972", "endSection": "abstract"}, {"offsetInBeginSection": 415, "offsetInEndSection": 734, "text": "In this cohort of medically refractory patients with CD, treatment with upadacitinib resulted in subjective and objective responses in 25 and 42% of patients, respectively. Even at doses that are considered lower than currently being studied for CD, upadacitinib was associated with a favorable benefit-to-risk profile.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35695972", "endSection": "abstract"}, {"offsetInBeginSection": 709, "offsetInEndSection": 798, "text": "Upadacitinib also showed promising results in a phase II trial in moderate to severe CD. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31781755", "endSection": "abstract"}]}, {"body": "Has MDMA(ecstasy) been successfully used to treat PTSD disorder?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37611653", "http://www.ncbi.nlm.nih.gov/pubmed/37484678", "http://www.ncbi.nlm.nih.gov/pubmed/36184377"], "ideal_answer": "Yes, MDMA (ecstasy) has shown promising results in the treatment of posttraumatic stress disorder (PTSD) when used in conjunction with psychotherapy. Clinical trials have demonstrated its safety and efficacy, leading to a resurgence of interest in this treatment approach. However, the exact mechanisms underlying its therapeutic effects are still not fully understood.", "exact_answer": "yes", "type": "yesno", "id": "65f490fac4010b4d78000010", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 336, "text": "The application of MDMA in conjunction with psychotherapy has in recent years seen a resurgence of clinical, scientific, and public interest in the treatment of posttraumatic stress disorder (PTSD). Clinical trials have shown promising safety and efficacy, but the mechanisms underlying this treatment form remain largely unestablished.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37611653", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "MDMA-assisted psychotherapy for PTSD: Growing evidence for memory effects mediating treatment efficacy", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37611653", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 381, "text": "Post-traumatic stress disorder (PTSD) is a prevalent psychiatric condition that significantly impacts daily functioning in patients but lacks adequate treatment options. 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy for the treatment of PTSD has been studied increasingly for the last two decades and has shown promising results through quantitative data.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37484678", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 301, "text": "Psychedelics and related compounds have shown efficacy for the treatment of a variety of conditions that are prevalent among older adults, including mood disorders, the psychological distress associated with a serious medical illness, post-traumatic stress disorder (PTSD), and prolonged grief disorde", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36184377", "endSection": "abstract"}]}, {"body": "Which age group should never be tested for HIV infection?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34949518", "http://www.ncbi.nlm.nih.gov/pubmed/37720974", "http://www.ncbi.nlm.nih.gov/pubmed/36629794", "http://www.ncbi.nlm.nih.gov/pubmed/36630307", "http://www.ncbi.nlm.nih.gov/pubmed/36630617"], "ideal_answer": "There is no age group that should never be tested for HIV infection. HIV testing is recommended for all individuals, regardless of age, as early diagnosis and treatment can improve outcomes and prevent transmission.", "exact_answer": [["There is no age group that should never be tested for HIV infection."]], "type": "factoid", "id": "65f86ba3c4010b4d78000059", "snippets": [{"offsetInBeginSection": 293, "offsetInEndSection": 410, "text": "social and clinical inequalities of more children infected with HIV and more children losing their fight against AIDS", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34949518", "endSection": "abstract"}, {"offsetInBeginSection": 475, "offsetInEndSection": 553, "text": "two out of five children living with HIV worldwide are unaware of their status", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34949518", "endSection": "abstract"}, {"offsetInBeginSection": 635, "offsetInEndSection": 721, "text": "Discrimination and gender inequalities permeate significant situations in HIV services", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34949518", "endSection": "abstract"}, {"offsetInBeginSection": 862, "offsetInEndSection": 882, "text": "maternal HIV testing", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34949518", "endSection": "abstract"}, {"offsetInBeginSection": 944, "offsetInEndSection": 968, "text": "pregnant people with HIV", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37720974", "endSection": "abstract"}, {"offsetInBeginSection": 1645, "offsetInEndSection": 1741, "text": "PPHIV experienced higher rates of LBW and VLBW newborns, and higher late pregnancy-related death", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37720974", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 196, "text": "adults diagnosed late with HIV", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36629794", "endSection": "abstract"}, {"offsetInBeginSection": 1545, "offsetInEndSection": 1720, "text": "HIV diagnosis could help develop effective strategies to reduce this burden of late presentation - particularly among heterosexual individuals, non-Europeans, and older people", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36629794", "endSection": "abstract"}, {"offsetInBeginSection": 1164, "offsetInEndSection": 1357, "text": "heterosexuals, older age, tested because symptomatic, and Pacific ethnicity were associated with late presentation, and M\u0101ori, Pacific and Asian people were more likely to have advanced disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36629794", "endSection": "abstract"}, {"offsetInBeginSection": 926, "offsetInEndSection": 1010, "text": "Amongst MSM, those who were older, of an ethnicity other than European, acquired HIV", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36629794", "endSection": "abstract"}, {"offsetInBeginSection": 485, "offsetInEndSection": 581, "text": "penile cancer within HIV-positive individuals is significantly greater than in those without HIV", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36630307", "endSection": "abstract"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1109, "text": "HIV and penile carcinoma, with a higher risk of cancer in Hispanic, compared with Caucasian, HIV-positive men", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36630307", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 149, "text": "The vulnerability of female sex workers (FSWs) to HIV infection increases if unprotected heterosexual anal intercourse (HAI) is practiced", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36630617", "endSection": "abstract"}]}, {"body": "Should all babies diagnosed with spina bifida be operated within the first week of life?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35735913", "http://www.ncbi.nlm.nih.gov/pubmed/30486637"], "ideal_answer": "No, not all babies diagnosed with spina bifida should be operated within the first week of life. With advancements in fetal treatment, prenatal surgery for spina bifida has shown improved outcomes compared to standard postnatal surgery. Fetoscopic spina bifida repair, a minimally invasive prenatal surgery, has been found to decrease the rate of ventriculoperitoneal shunt placement and improve motor function. Therefore, prenatal surgery should be considered as a realistic option for the treatment of spina bifida.", "exact_answer": "no", "type": "yesno", "id": "65f859b2c4010b4d78000050", "snippets": [{"offsetInBeginSection": 324, "offsetInEndSection": 475, "text": "treatment for spina bifida has made great advancements, from surgical closure of the defect after birth to the now state-of-the-art intrauterine repair", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35735913", "endSection": "abstract"}, {"offsetInBeginSection": 363, "offsetInEndSection": 479, "text": "Advances in fetal treatment have made minimally invasive prenatal surgery a realistic consideration for spina bifida", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30486637", "endSection": "abstract"}, {"offsetInBeginSection": 571, "offsetInEndSection": 770, "text": "Prenatal surgery for spina bifida via open fetal surgery with hysterotomy decreases the rate of ventriculoperitoneal shunt placement and improves motor function compared to standard postnatal surgery", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30486637", "endSection": "abstract"}, {"offsetInBeginSection": 1643, "offsetInEndSection": 1673, "text": "fetoscopic spina bifida repair", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30486637", "endSection": "abstract"}, {"offsetInBeginSection": 2124, "offsetInEndSection": 2158, "text": "prenatal treatment of spina bifida", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30486637", "endSection": "abstract"}]}, {"body": "Which symptoms could indicate depression in young children?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33436094"], "ideal_answer": "Symptoms that could indicate depression in young children include persistent sadness or irritability, loss of interest in activities, changes in appetite or weight, sleep disturbances, fatigue or low energy, difficulty concentrating or making decisions, feelings of worthlessness or guilt, recurrent thoughts of death or suicide, physical complaints without a clear medical cause, and social withdrawal or isolation.", "exact_answer": [["Persistent sadness or irritability"], ["Loss of interest or pleasure in activities"], ["Changes in appetite or weight"], ["Sleep disturbances"], ["Fatigue or loss of energy"]], "type": "list", "id": "65f86f62c4010b4d7800005c", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 196, "text": "Major depressive disorder is common, debilitating, and affects feelings, thoughts, mood, and behaviors. Childhood and adolescence are critical periods for the development of depression", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33436094", "endSection": "abstract"}, {"offsetInBeginSection": 1140, "offsetInEndSection": 1151, "text": "suicidality", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33436094", "endSection": "abstract"}, {"offsetInBeginSection": 1212, "offsetInEndSection": 1301, "text": "lifestyle behavior (e.g., substance use, school performance, lost time at work, or school", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33436094", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of Pegozafermin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37355760", "http://www.ncbi.nlm.nih.gov/pubmed/36521501", "http://www.ncbi.nlm.nih.gov/pubmed/37356033", "http://www.ncbi.nlm.nih.gov/pubmed/37696614", "http://www.ncbi.nlm.nih.gov/pubmed/37562970"], "ideal_answer": "Pegozafermin is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21). It activates human FGF receptors and improves metabolic and liver outcomes.", "type": "summary", "id": "65cfab681930410b13000012", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "Pegozafermin, a long-acting glycopegylated analog of human fibroblast growth factor 21, is in development for the treatment of severe hypertriglyceridemia (SHTG) and nonalcoholic steatohepatitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37355760", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37355760", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 342, "text": "BACKGROUND: Management strategies for non-alcoholic steatohepatitis (NASH) are based predominantly on lifestyle modification, with no approved disease-modifying drugs yet available. We aimed to evaluate the safety, pharmacokinetics, and pharmacodynamics of pegozafermin (BIO89-100), a glycoPEGylated FGF21 analogue, in participants with NASH.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36521501", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37356033", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 270, "text": "BACKGROUND: Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37356033", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "Pegozafermin is a long-acting glycoPEGylated analog of fibroblast growth factor 21 (FGF21) in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37696614", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37562970", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Pegozafermin (also known as BIO89-100) is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) under development to treat nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37562970", "endSection": "abstract"}]}, {"body": "What is Oculopharyngeal Muscular Dystrophy (OPMD)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33805441", "http://www.ncbi.nlm.nih.gov/pubmed/35942670"], "ideal_answer": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset intractable myopathy characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness. It is a neuromuscular disease that primarily affects the muscles involved in eye movement, swallowing, and limb movement.", "type": "summary", "id": "6446884b57b1c7a31500006f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset intractable myopathy, characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33805441", "endSection": "abstract"}, {"offsetInBeginSection": 19, "offsetInEndSection": 210, "text": "Oculopharyngodistal myopathy (OPDM) is a rare adolescent or adult-onset neuromuscular disease that is characterized by progressive ocular, facial, pharyngeal and distal limb muscle weakness. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35942670", "endSection": "abstract"}]}, {"body": "What is the pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32825236", "http://www.ncbi.nlm.nih.gov/pubmed/24071482", "http://www.ncbi.nlm.nih.gov/pubmed/30151274"], "ideal_answer": "Perturbations of the colonic microbiota can lead to an increase in pathogenic bacteria and a decrease in protective bacteria. This imbalance can result in the production of carcinogenic metabolites/toxins, induction of inflammation, and activation of oncogenic signaling. Pathogenic bacteria often have heightened iron acquisition mechanisms, allowing them to outcompete protective bacteria for free iron.", "type": "summary", "id": "65f77328c4010b4d78000023", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 347, "text": "Perturbations of the colonic microbiota can contribute to the initiation and progression of colorectal cancer, leading to an increase in pathogenic bacteria at the expense of protective bacteria. This can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32825236", "endSection": "abstract"}, {"offsetInBeginSection": 672, "offsetInEndSection": 807, "text": "Most pathogenic bacteria have heightened iron acquisition mechanisms and therefore tend to outcompete protective bacteria for free iron", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32825236", "endSection": "abstract"}, {"offsetInBeginSection": 331, "offsetInEndSection": 532, "text": "alterations in communication between the mucosal immune system and gut microbial communities have been implicated as the core defect that leads to chronic intestinal inflammation and cancer development", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24071482", "endSection": "abstract"}, {"offsetInBeginSection": 687, "offsetInEndSection": 894, "text": "multiple proposed pathogenic microorganisms including sulfidogenic bacteria such as Bilophila wadsworthia, as well as Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30151274", "endSection": "abstract"}]}, {"body": "Brunner's gland hamartoma (BGH) is often asymptomatic and so how is it usually diagnosed?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30671231", "http://www.ncbi.nlm.nih.gov/pubmed/27737521", "http://www.ncbi.nlm.nih.gov/pubmed/22303509", "http://www.ncbi.nlm.nih.gov/pubmed/15034292"], "ideal_answer": "Brunner's gland hamartoma (BGH) is often asymptomatic and is usually diagnosed incidentally during esophagogastroduodenoscopy (EGD) or upper gastrointestinal series (UGI).", "type": "summary", "id": "65f59db8c4010b4d78000014", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "Brunner's gland hamartoma is a rare benign duodenal tumor. It occurs in Brunner's glands, which are found in the duodenum and produce secretions that protect the duodenum from pancreatic enzymes, gastric acid, and other agents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30671231", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "Brunner's gland hamartomas are small benign lesions that are most commonly found in the bulb of the duodenum. They are very uncommon, and most are found incidentally during upper gastrointestinal series or esophagogastroduodenoscopy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27737521", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Brunner's gland hamartoma is an extremely uncommon benign tumor of the duodenum. Most of the lesions are small, asymptomatic and are detected incidentally. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22303509", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Brunner's gland hamartomas are rare tumors of duodenum, they are often discovered incidentally during esophagogastroduodenoscopy or upper gastrointestinal series", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15034292", "endSection": "abstract"}]}, {"body": "Please list the Janus Kinase inhibitors used to treat Inflammatory Bowel Disease(IBD)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36936239", "http://www.ncbi.nlm.nih.gov/pubmed/36515243", "http://www.ncbi.nlm.nih.gov/pubmed/36913180", "http://www.ncbi.nlm.nih.gov/pubmed/37004800", "http://www.ncbi.nlm.nih.gov/pubmed/37855324"], "ideal_answer": "The Janus Kinase (JAK) inhibitors used to treat Inflammatory Bowel Disease (IBD) include tofacitinib, upadacitinib, filgotinib, and deucravacitinib.", "exact_answer": [["Tofacitinib"], ["Upadacitinib"], ["Filgotinib"], ["Deucravacitinib"]], "type": "list", "id": "65f1d234c4010b4d78000005", "snippets": [{"offsetInBeginSection": 1073, "offsetInEndSection": 1323, "text": "Although there are currently no approved JAK inhibitors for Crohn's disease, upadacitinib and filgotinib have shown increased remission rates in these patients. Other JAK inhibitors, including gut-selective molecules, are currently being studied IBD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36936239", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 151, "text": "he Clinical Response of Upadacitinib and Risankizumab Is Associated With Reduced Inflammatory Bowel Disease Anti-TNF-\u03b1 Inadequate Response Mechanisms.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36515243", "endSection": "title"}, {"offsetInBeginSection": 340, "offsetInEndSection": 533, "text": "Tofacitinib, a non-selective small molecule JAK inhibitor, and\u00a0upadacitinib and filgotinib, which are selective JAK-1 inhibitors, have been approved by the US Food and Drug Administration (FDA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36913180", "endSection": "abstract"}, {"offsetInBeginSection": 237, "offsetInEndSection": 323, "text": "Tofacitinib, a pan-JAK inhibitor, has spearheaded the new JAK class for IBD treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37004800", "endSection": "abstract"}, {"offsetInBeginSection": 532, "offsetInEndSection": 1404, "text": " We conducted a comparative phosflow study of four JAKinibs (filgotinib, upadacitinib, tofacitinib, and deucravacitinib) to observe subtle mechanistic differences that may dictate their clinical behavior. Resected mesenteric lymph node (MLN) cells from 19 patients (9 CD, 10 UC) were analyzed by flow cytometry in the presence or absence of different cytokine stimuli and titrated JAKinibs.RESULTS: We found a higher potency of the JAK 1/3-preferential inhibitor, tofacitinib, for JAK 3-dependent cytokine signaling pathways in comparison to filgotinib, but a higher potency of the JAK 1-preferential inhibitors, filgotinib and upadacitinib, for JAK 3-independent cytokine signaling pathways. Deucravacitinib, a TYK2-preferential inhibitor, demonstrated a much narrower selectivity by inhibiting only IL-10 and IFN-\u03b2pathways, albeit more potently than the other JAKinibs .", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37855324", "endSection": "abstract"}]}, {"body": "Which neurotransmitters are thought to play a role in obsessive compulsive disorder?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33751503"], "ideal_answer": "Serotonin and dopamine are thought to play a role in obsessive-compulsive disorder (OCD). Serotonin is involved in regulating mood, anxiety, and impulse control, while dopamine is associated with reward and motivation. Dysfunction in these neurotransmitter systems may contribute to the development and symptoms of OCD.", "exact_answer": [["serotonin"], ["dopamine"], ["glutamate"]], "type": "list", "id": "65f8721ec4010b4d7800005d", "snippets": [{"offsetInBeginSection": 765, "offsetInEndSection": 844, "text": "three neurotransmitter systems in the brain: serotonin, dopamine, and glutamate", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33751503", "endSection": "abstract"}]}, {"body": "Is Marburg virus a member of the family of the Ebola virus (Filoviridae)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31021739", "http://www.ncbi.nlm.nih.gov/pubmed/36084314"], "ideal_answer": "Yes, Marburg virus is a member of the family Filoviridae, which also includes the Ebola virus. Both Marburg virus and Ebola virus belong to the filoviruses, a group of viruses known for causing severe hemorrhagic fever in humans.", "exact_answer": "yes", "type": "yesno", "id": "65f86f03c4010b4d7800005b", "snippets": [{"offsetInBeginSection": 261, "offsetInEndSection": 313, "text": "Several filoviruses infect bats (e.g., Marburg virus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31021739", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 48, "text": "African Filovirus (Ebola and Marburg)", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36084314", "endSection": "title"}, {"offsetInBeginSection": 527, "offsetInEndSection": 571, "text": "filoviruses (ebolaviruses and Marburg virus)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36084314", "endSection": "abstract"}]}, {"body": "Is sectoral Heterochromia associated with Crohn's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34189344", "http://www.ncbi.nlm.nih.gov/pubmed/17933676", "http://www.ncbi.nlm.nih.gov/pubmed/3792843"], "ideal_answer": "No, sectoral heterochromia is not associated with Crohn's disease. Sectoral heterochromia refers to a condition where there is a difference in color within a single iris. It is typically a benign and isolated finding, not associated with any specific medical condition. Crohn's disease, on the other hand, is a chronic inflammatory bowel disease that primarily affects the gastrointestinal tract. The two conditions are unrelated and have different underlying mechanisms and clinical presentations.", "exact_answer": "no", "type": "yesno", "id": "65cfd68a1930410b13000021", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "A case of unilateral sectoral iris heterochromia in an infant with Beckwith-Wiedemann syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34189344", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "PURPOSE: To report a case of unilateral sectoral iris heterochromia in an infant with Beckwith-Wiedemann syndrome (BWS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34189344", "endSection": "abstract"}, {"offsetInBeginSection": 367, "offsetInEndSection": 451, "text": "CONCLUSIONS: This is the first reported case of iris heterochromia in a BWS patient.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34189344", "endSection": "abstract"}, {"offsetInBeginSection": 51, "offsetInEndSection": 262, "text": "The first case is an example of Waardenburg's type II (without dystopia canthorum) with bilateral sectoral iris heterochromia and fundus bicolor, hyperpigmented skin patches, characteristic facies and deafness. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3792843", "endSection": "abstract"}]}, {"body": "Is it advisable to bring the fever down when it is supposedly meant to assist in the fight of disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35967183", "http://www.ncbi.nlm.nih.gov/pubmed/35511631", "http://www.ncbi.nlm.nih.gov/pubmed/33912381"], "ideal_answer": "Fever is a common symptom in children and is usually a sign that the body is fighting off an infection. Antipyretics, such as acetaminophen or ibuprofen, are indicated for relieving discomfort caused by fever, but they should not be given solely to reduce body temperature. The primary goal of treating fever is to provide comfort to the patient, rather than to suppress the body's natural defense mechanisms.", "type": "summary", "id": "65f8418fc4010b4d78000041", "snippets": [{"offsetInBeginSection": 13, "offsetInEndSection": 112, "text": "Fever is the most common presenting symptom in children and causes distress in patients and parents", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35967183", "endSection": "abstract"}, {"offsetInBeginSection": 500, "offsetInEndSection": 546, "text": "antipyretics are indicated only for discomfort", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35511631", "endSection": "abstract"}, {"offsetInBeginSection": 1504, "offsetInEndSection": 1680, "text": "relief from distress is the primary indication for prescribing pharmacotherapy, and antipyretics should not be administered with the sole intention of reducing body temperature", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33912381", "endSection": "abstract"}]}, {"body": "Are only babies and young children at risk of severe malaria in endemic areas?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37365258", "http://www.ncbi.nlm.nih.gov/pubmed/35916146", "http://www.ncbi.nlm.nih.gov/pubmed/34905777", "http://www.ncbi.nlm.nih.gov/pubmed/35382261"], "ideal_answer": "No, severe malaria can affect individuals of all ages in endemic areas. While babies and young children are particularly vulnerable, adults can also develop severe forms of malaria, including cerebral malaria. Brain involvement is common in adults with severe malaria, and cerebral malaria can be rapidly progressive and severe, often leading to fatal outcomes even in treated individuals.", "exact_answer": "no", "type": "yesno", "id": "65f83281c4010b4d78000040", "snippets": [{"offsetInBeginSection": 68, "offsetInEndSection": 168, "text": "malaria in pregnancy remains a significant cause of low birth weight, stillbirth, and severe anaemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37365258", "endSection": "abstract"}, {"offsetInBeginSection": 139, "offsetInEndSection": 205, "text": "mortality rates from severe malaria (SM) remain significantly high", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35916146", "endSection": "abstract"}, {"offsetInBeginSection": 546, "offsetInEndSection": 571, "text": "SM in adults and children", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35916146", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 38, "text": "Cerebral malaria in adults", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34905777", "endSection": "abstract"}, {"offsetInBeginSection": 1258, "offsetInEndSection": 1306, "text": "Brain involvement is common in adults with SNCM ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34905777", "endSection": "abstract"}, {"offsetInBeginSection": 117, "offsetInEndSection": 214, "text": "Cerebral malaria (CM) is a rapidly progressive and severe form of Plasmodium falciparum infection", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35382261", "endSection": "abstract"}, {"offsetInBeginSection": 480, "offsetInEndSection": 638, "text": "CM, often associated with fatal outcomes even in treated subjects, is usually diagnosed at autopsy.Case presentation: We present the case of a 36-year-old man", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35382261", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of Peresolimab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37195941"], "ideal_answer": "Peresolimab is a humanized IgG1 monoclonal antibody that stimulates the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway.", "type": "summary", "id": "65d128f81930410b1300002d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "BACKGROUND: Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37195941", "endSection": "abstract"}, {"offsetInBeginSection": 1941, "offsetInEndSection": 2175, "text": "CONCLUSIONS: Peresolimab showed efficacy in a phase 2a trial in patients with rheumatoid arthritis. These results provide evidence that stimulation of the PD-1 receptor has potential efficacy in the treatment of rheumatoid arthritis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37195941", "endSection": "abstract"}]}, {"body": "Which dietary compounds are associated with colorectal cancer incidence?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33591366", "http://www.ncbi.nlm.nih.gov/pubmed/34455534"], "ideal_answer": "Lower intake of dietary fiber, dietary calcium, and yogurt are associated with higher risk of colorectal cancer. On the other hand, higher intake of alcohol and red meat, particularly processed meat, is associated with an increased risk of colorectal cancer.", "exact_answer": [["dietary fiber"], ["dietary calcium"], ["yogurt"], ["alcohol"], ["red meat"]], "type": "list", "id": "65f7725ec4010b4d78000020", "snippets": [{"offsetInBeginSection": 2093, "offsetInEndSection": 2288, "text": "This umbrella review found convincing evidence of an association between lower CRC risk and higher intakes of dietary fiber, dietary calcium, and yogurt and lower intakes of alcohol and red meat.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33591366", "endSection": "abstract"}, {"offsetInBeginSection": 1826, "offsetInEndSection": 2134, "text": "high red meat intake was positively\u00a0associated with risk of breast cancer, endometrial cancer,\u00a0colorectal cancer, colon cancer, rectal cancer, lung cancer, and hepatocellular carcinoma, and high processed meat intake was positively\u00a0associated with risk of breast, colorectal, colon,\u00a0rectal, and lung cancers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34455534", "endSection": "abstract"}, {"offsetInBeginSection": 2135, "offsetInEndSection": 2276, "text": "Higher risk of colorectal, colon, rectal, lung, and renal cell cancers were also observed with high total red and processed meat consumption.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34455534", "endSection": "abstract"}]}, {"body": "What is prurigo nodularis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37506977", "http://www.ncbi.nlm.nih.gov/pubmed/37245863", "http://www.ncbi.nlm.nih.gov/pubmed/36806647"], "ideal_answer": "Prurigo nodularis (PN) is a chronic neuroimmune skin disease characterized by pruritic hyperkeratotic nodules on the extremities and trunk. It is an understudied inflammatory skin disease that presents with extremely pruritic, hyperkeratotic nodules. PN is a chronic inflammatory skin disease that causes intense itching and the formation of nodules on the skin.", "type": "summary", "id": "65f1eb84c4010b4d78000008", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 173, "text": "Prurigo nodularis (PN) is a chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk. N", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37506977", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Prurigo nodularis (PN) is an understudied inflammatory skin disease characterized by pruritic, hyperkeratotic nodules. I", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37245863", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 95, "text": "Prurigo nodularis (PN) is an extremely pruritic, chronic inflammatory skin disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36806647", "endSection": "abstract"}]}, {"body": "Is melatonin beneficial in the treatment of in cerebral ischemia-reperfusion injury:", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37301531", "http://www.ncbi.nlm.nih.gov/pubmed/37321200", "http://www.ncbi.nlm.nih.gov/pubmed/35219702"], "ideal_answer": "Yes, melatonin is beneficial in the treatment of cerebral ischemia-reperfusion injury. It has been shown to attenuate brain injury by inducing autophagy, suppressing endoplasmic reticulum stress, and promoting synaptic plasticity. Melatonin regulates microglial polarization, which plays a crucial role in the pathogenesis of CNS diseases. Therefore, melatonin can be considered a promising neuroprotective agent for the treatment of cerebral ischemia-reperfusion injury.", "exact_answer": "yes", "type": "yesno", "id": "65f0369bc4010b4d78000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Melatonin regulates microglial polarization and protects against ischemic stroke-induced brain injury in mice.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37301531", "endSection": "title"}, {"offsetInBeginSection": 331, "offsetInEndSection": 461, "text": "Melatonin is a promising neuroprotective agent that can regulate microglial polarization in central nervous system (CNS) diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37301531", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Melatonin Attenuates Cerebral Ischemia/Reperfusion Injury through Inducing Autophagy", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37321200", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Melatonin improves cognitive function by suppressing endoplasmic reticulum stress and promoting synaptic plasticity during chronic cerebral hypoperfusion in rats.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35219702", "endSection": "title"}]}, {"body": "Explain the action of Domperidone.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37352416", "http://www.ncbi.nlm.nih.gov/pubmed/36958154"], "ideal_answer": "Domperidone is a dopamine-2 (D2) receptor antagonist that blocks the action of dopamine at the D2 receptors. By inhibiting dopamine, domperidone stimulates the release of prolactin from the anterior pituitary gland. This leads to an increase in prolactin levels, which can be beneficial in certain conditions such as lactation disorders.", "type": "summary", "id": "65f492bbc4010b4d78000011", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Domperidone is a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37352416", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Domperidone is a dopamine D2 receptor inhibitor that stimulates pituitary gonadotropins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36958154", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of sparsentan?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37180506", "http://www.ncbi.nlm.nih.gov/pubmed/37022667", "http://www.ncbi.nlm.nih.gov/pubmed/37256677", "http://www.ncbi.nlm.nih.gov/pubmed/37221817", "http://www.ncbi.nlm.nih.gov/pubmed/36852566"], "ideal_answer": "Sparsentan is a single-molecule dual antagonist of the endothelin type A receptor and angiotensin II type 1 receptor. It works by blocking the effects of both endothelin and angiotensin II, which are involved in the pathogenesis of renal diseases such as focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN).", "type": "summary", "id": "65cebf371930410b13000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Introduction: Sparsentan is a novel single-molecule dual endothelin angiotensin receptor antagonist with hemodynamic and anti-inflammatory properties and is not an immunosuppressant. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37180506", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "Sparsentan (FILSPARI\u2122) is an oral, dual endothelin angiotensin receptor antagonist that is being developed by Travere Therapeutics for the treatment of immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37022667", "endSection": "abstract"}, {"offsetInBeginSection": 275, "offsetInEndSection": 471, "text": "Sparsentan is a single-molecule dual endothelin type-A and angiotensin II type 1 receptor antagonist (DEARA) under clinical development for focal segmental glomerulosclerosis and IgA nephropathy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37256677", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "Sparsentan is a single-molecule dual endothelin angiotensin receptor antagonist (DEARA) currently under investigation as a treatment for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37221817", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "Sparsentan is a single-molecule dual antagonist of the endothelin type A receptor and angiotensin II type 1 receptor under investigation for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36852566", "endSection": "abstract"}]}, {"body": "Please list the congenital fibrinogen disorders.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37823427", "http://www.ncbi.nlm.nih.gov/pubmed/36055263", "http://www.ncbi.nlm.nih.gov/pubmed/35853369", "http://www.ncbi.nlm.nih.gov/pubmed/35821906", "http://www.ncbi.nlm.nih.gov/pubmed/35207353", "http://www.ncbi.nlm.nih.gov/pubmed/34261148", "http://www.ncbi.nlm.nih.gov/pubmed/36276905", "http://www.ncbi.nlm.nih.gov/pubmed/34829490"], "ideal_answer": "The congenital fibrinogen disorders include afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia.", "exact_answer": [["Afibrinogenemia"], ["Dysfibrinogenemia"], ["Hypodysfibrinogenemia"], ["Hypofibrinogenemia"]], "type": "list", "id": "65f70a55c4010b4d7800001b", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 352, "text": "Congenital fibrinogen deficiencies (CFD) are a group of rare bleeding disorders (RBD). Afibrinogenemia as a subclass of these disorders would occurs as a result of mutations in fibrinogen gene. Here in, the sequences of A\u03b1 chain of fibrinogen (FGA) in patients with inherited afibrinogenemia disorder in south-eastern of Iran were analysed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37823427", "endSection": "abstract"}, {"offsetInBeginSection": 134, "offsetInEndSection": 295, "text": " From the first clinical description of afibrinogenemia in 1920, many major achievements have contributed to a better understanding of these complex disorders. T", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36055263", "endSection": "abstract"}, {"offsetInBeginSection": 1431, "offsetInEndSection": 1514, "text": "congenital fibrinogen disorders, focusing on afibrinogenemia and dysfibrinogenemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36055263", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Ranging from bleeding to thrombosis, the clinical features of congenital fibrinogen qualitative disorders, including dysfibrinogenemia and hypodysfibrinogenemia, ar", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35853369", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Congenital (hypo-)dysfibrinogenemia and bleeding: A systematic literature review.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35853369", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "Fibrinogen deficiencies are very rare. Qualitative fibrinogen deficiencies (dysfibrinogenaemia and hypodysfibrinogenemia) are functional disorders that can present with both haemorrhagic symptoms and with thro", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35821906", "endSection": "abstract"}, {"offsetInBeginSection": 582, "offsetInEndSection": 773, "text": "In this paper, we focused on familial hypofibrinogenemia, a rare inherited quantitative fibrinogen disorder characterized by decreased fibrinogen levels with a high phenotypic heterogeneity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35207353", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 258, "text": "The congenital dysfibrinogenemias, most often associated with bleeding disorders, encompass mutations in the amino-terminal end of fibrinogen \u03b1-chain consisting of Gly17-Pro18-Arg19-Val20, known as knob A, which is a critical site for fibrin polymerization. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34261148", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 88, "text": " case of congenital afibrinogenemia with multiple thrombotic and hemorrhagic disorders.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36276905", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Congenital fibrinogen disorders are rare pathologies of the hemostasis, comprising quantitative (afibrinogenemia, hypofibrinogenemia) and qualitative (dysfibrinogenemia and hypodysfibrinogenemia) disorders. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34829490", "endSection": "abstract"}]}, {"body": "What is the first line treatment for severe Plasmodium falciparum malaria?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36056897", "http://www.ncbi.nlm.nih.gov/pubmed/37666798", "http://www.ncbi.nlm.nih.gov/pubmed/36126008"], "ideal_answer": "The first-line treatment for severe Plasmodium falciparum malaria is intravenous artesunate.", "exact_answer": [["The first-line treatment for severe Plasmodium falciparum malaria is intravenous artesunate."]], "type": "factoid", "id": "65f82058c4010b4d7800003d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Intravenous artesunate has been the global standard of care for severe malaria", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36056897", "endSection": "abstract"}, {"offsetInBeginSection": 67, "offsetInEndSection": 152, "text": "Parenteral artesunate (ARS) is the first-line treatment for severe falciparum malaria", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37666798", "endSection": "abstract"}, {"offsetInBeginSection": 1560, "offsetInEndSection": 1628, "text": "Intravenous artesunate is the treatment of choice for severe malaria", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36126008", "endSection": "abstract"}]}, {"body": "Can denosumab cause jaw necrosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32307659", "http://www.ncbi.nlm.nih.gov/pubmed/29063702", "http://www.ncbi.nlm.nih.gov/pubmed/28684826", "http://www.ncbi.nlm.nih.gov/pubmed/25497376", "http://www.ncbi.nlm.nih.gov/pubmed/23830772"], "ideal_answer": "Yes, denosumab can cause jaw necrosis, a condition known as medication-related osteonecrosis of the jaw (MRONJ). MRONJ is a potential adverse event that can occur after exposure to bone-modifying agents, including denosumab.", "exact_answer": "yes", "type": "yesno", "id": "65d126d21930410b1300002c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "BACKGROUND: Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but potentially serious, adverse event that can occur after exposure to bone-modifying agents (BMAs; e.g., bisphosphonates, denosumab, and antiangiogenic therapies). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32307659", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 237, "text": "Osteonecrosis of the jaw (ONJ) is a severe complication of therapy with antiresorptive agents (e.g. bisphosphonates and denosumab), which are used to manage bone metastases from cancer, to reduce the incidence of skeletal-related events.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29063702", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "Aggressive denosumab-related jaw necrosis - a case series.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28684826", "endSection": "title"}, {"offsetInBeginSection": 203, "offsetInEndSection": 329, "text": "We are presenting four cases of MRONJ related to denosumab treatment showing increasingly aggressive pictures of the disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28684826", "endSection": "abstract"}, {"offsetInBeginSection": 476, "offsetInEndSection": 767, "text": "A total of 383 cases were registered: 369 were described as BRONJ, 5 as avascular necrosis, and 9 were unknown. Bisphosphonates had been given orally in 207 (56%), intravenously in 125 (34%), both orally and intravenously in 27 (7%), and was unknown in 9 (2%); one had been given denosumab. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25497376", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Osteonecrosis of the jaw has recently been described in patients receiving subcutaneous administration of RANKL-inhibitors (denosumab).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23830772", "endSection": "abstract"}]}, {"body": "What are the most common symptoms of fibroids?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36759100", "http://www.ncbi.nlm.nih.gov/pubmed/36989026"], "ideal_answer": "The most common symptoms of fibroids include heavy menstrual bleeding leading to anemia, pelvic pressure, pain during periods, protrusion of the abdomen, pain during intercourse, urinary and bowel dysfunctions, and reproductive issues such as impaired fertility and adverse obstetric outcomes.", "exact_answer": [["Heavy menstrual bleeding"], ["Pelvic pressure"], ["Pain"], ["Abnormal menstrual bleeding leading to anemia"], ["Tiredness"]], "type": "list", "id": "65f84aa5c4010b4d78000047", "snippets": [{"offsetInBeginSection": 66, "offsetInEndSection": 162, "text": "Fibroids can be asymptomatic or present with heavy menstrual bleeding, pelvic pressure, and pain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36759100", "endSection": "abstract"}, {"offsetInBeginSection": 309, "offsetInEndSection": 755, "text": "Uterine fibroid symptoms include abnormal menstrual bleeding leading to anaemia, tiredness, chronic vaginal discharge, and pain during periods. Other symptoms include protrusion of the abdomen, pain during intercourse, dysfunctions of bladder/bowel leading to urinary incontinence/retention, pain, and constipation. It is also associated with reproductive issues like impaired fertility, conceiving complications, and adverse obstetric outcomes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36989026", "endSection": "abstract"}]}, {"body": "How can Emery-Dreifuss Muscular Dystrophy (EDMD) be inherited?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30506906", "http://www.ncbi.nlm.nih.gov/pubmed/28214269", "http://www.ncbi.nlm.nih.gov/pubmed/27179216", "http://www.ncbi.nlm.nih.gov/pubmed/21496632"], "ideal_answer": "Emery-Dreifuss Muscular Dystrophy (EDMD) can be inherited in an X-linked recessive, autosomal dominant, or autosomal recessive fashion. The majority of EDMD cases are of the emerinopathy (EDMD1) kind, which is inherited in a recessive X-linked manner. Another form, known as laminopathy (EDMD2), is inherited in an autosomal dominant manner. EDMD is also associated with defects of the cardiac conduction system, which can lead to sudden death.", "exact_answer": [["Emery-Dreifuss Muscular Dystrophy (EDMD) can be inherited in three different ways:"], ["1. X-linked recessive: The majority of EDMD cases are of the emerinopathy (EDMD1) kind, with a recessive X-linked mode of inheritance. This means that the disorder is caused by mutations in the emerin gene located on the X chromosome. Males are more commonly affected by this type of EDMD, while females are usually carriers."], ["2. Autosomal dominant: Some cases of EDMD are caused by mutations in the lamin A gene, which follows an autosomal dominant mode of inheritance. This means that a single copy of the mutated gene from either parent is sufficient to cause the disorder. Both males and females can be affected by this type of EDMD."], ["3. Autosomal recessive: In rare cases, EDMD can be inherited in an autosomal recessive manner. This means that both copies of the gene responsible for the disorder must be mutated for an individual to be affected. Both males and females can be affected by this type of EDMD."], ["It is important to note that EDMD is also associated with defects of the cardiac conduction system, which can lead to sudden death."]], "type": "list", "id": "64467f8657b1c7a31500006d", "snippets": [{"offsetInBeginSection": 207, "offsetInEndSection": 239, "text": "X-linked recessive EDMD patient ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30506906", "endSection": "abstract"}, {"offsetInBeginSection": 401, "offsetInEndSection": 713, "text": " Therefore, myoblast/fibroblast cultures from biopsy and tissue sections from a panel of nine Emery-Dreifuss muscular dystrophy patients (4 male, 5 female) including those carrying emerin and FHL1 (X-linked) and several lamin A (autosomal dominant) mutations were stained for the proteins linked to the disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28214269", "endSection": "abstract"}, {"offsetInBeginSection": 373, "offsetInEndSection": 581, "text": "he majority of the EDMD cases described so far are of the emerinopathy (EDMD1) kind, with a recessive X-linked mode of inheritance, or else laminopathy (EDMD2), with an autosomal dominant mode of inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27179216", "endSection": "abstract"}, {"offsetInBeginSection": 155, "offsetInEndSection": 429, "text": "EDMD is also distinctive for its association with defects of the cardiac conduction system that can result in sudden death. It can be inherited in an X-linked, autosomal dominant, or autosomal recessive fashion and is caused by mutations in proteins of the nuclear membrane.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21496632", "endSection": "abstract"}]}, {"body": "Is there an approved vaccine against Helicobacter pylori?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37018869", "http://www.ncbi.nlm.nih.gov/pubmed/37971157"], "ideal_answer": "No, there is currently no approved vaccine against Helicobacter pylori. Despite more than 30 years of research, no vaccine has entered the market yet. However, there have been advances in the development of H. pylori vaccines, including the identification of potential antigens and adjuvants, which provide references for future vaccine development against this bacterium.", "exact_answer": "no", "type": "yesno", "id": "65f86a90c4010b4d78000057", "snippets": [{"offsetInBeginSection": 183, "offsetInEndSection": 416, "text": "H. pylori, the development of an efficacious vaccine is a valid option to protect from disease or infection and ultimately prevent gastric cancer. However, despite more than 30 years of research, no vaccine has entered the market yet", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37018869", "endSection": "abstract"}, {"offsetInBeginSection": 2265, "offsetInEndSection": 2427, "text": "advances of H. pylori vaccines from two aspects, candidates of antigens and adjuvants, to provide references for the development of vaccine against this bacterium", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971157", "endSection": "abstract"}]}, {"body": "Can fingolimod be used during pregnancy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37307691", "http://www.ncbi.nlm.nih.gov/pubmed/35428205", "http://www.ncbi.nlm.nih.gov/pubmed/35390594", "http://www.ncbi.nlm.nih.gov/pubmed/35088492", "http://www.ncbi.nlm.nih.gov/pubmed/33443836", "http://www.ncbi.nlm.nih.gov/pubmed/34310364"], "ideal_answer": "No, fingolimod should not be used during pregnancy due to the suspected risk of congenital malformations. Fingolimod is contraindicated in pregnant women, and alternative treatment options should be considered.", "exact_answer": "no", "type": "yesno", "id": "65d12ae11930410b13000030", "snippets": [{"offsetInBeginSection": 1570, "offsetInEndSection": 1775, "text": "Interferon beta 1a SC was preferred over other treatments for patients with mild to moderate MS and planning for pregnancy (56.6%) or breastfeeding (60.2%). Fingolimod was not a choice for these patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37307691", "endSection": "abstract"}, {"offsetInBeginSection": 1985, "offsetInEndSection": 2389, "text": "In total, 45 patients (18.8%) permanently discontinued treatment because of AEs related to study drug; two patients reported pregnancy after treatment initiation and subsequently discontinued the\u00a0treatment; no deaths were reported.CONCLUSION: GOLEMS study demonstrated the sustained effectiveness and manageable safety profile of fingolimod under real-world conditions over 48\u00a0months in patients with MS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35428205", "endSection": "abstract"}, {"offsetInBeginSection": 1568, "offsetInEndSection": 1893, "text": "Concerns about COVID-19 had a noticeable impact on administering high efficacy drugs like rituximab and fingolimod. However, in male patients this approach has not been the case. It may be related to more aggressive disease course in this group. The other possible explanation could be planning for pregnancy in female cases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35390594", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "BACKGROUND: Authorizations of fingolimod, teriflunomide and cladribine were accompanied by risk minimization measures concerning their teratogenic potential.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36174258", "endSection": "abstract"}, {"offsetInBeginSection": 503, "offsetInEndSection": 600, "text": "Fingolimod\u2005: contraindicated during pregnancy due to suspected risk of congenital malformations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33443836", "endSection": "abstract"}, {"offsetInBeginSection": 489, "offsetInEndSection": 706, "text": "Drugs with a known potential of teratogenicity such as fingolimod or teriflunomide should be avoided and recommended wash-out times for medications such as cladribine, alemtuzumab or ocrelizumab should be considered. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34310364", "endSection": "abstract"}]}, {"body": "Which are the two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32801927", "http://www.ncbi.nlm.nih.gov/pubmed/31430318"], "ideal_answer": "The two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis) are tenofovir and emtricitabine.", "exact_answer": [["tenofovir"], ["emtricitabine"]], "type": "list", "id": "65f85231c4010b4d7800004d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Pre-exposure prophylaxis (PrEP) against HIV infection with tenofovir/emtricitabine", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32801927", "endSection": "abstract"}, {"offsetInBeginSection": 32, "offsetInEndSection": 55, "text": "emtricitabine/tenofovir", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31430318", "endSection": "abstract"}]}, {"body": "What proportion of alteration in NTRK genes are attributable to colorectal cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36914665"], "ideal_answer": "The proportion of alterations in NTRK genes attributable to colorectal cancer is consistently below 0.5%. However, it is important to note that rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers may have higher rates of NTRK gene alterations.", "exact_answer": [["The proportion of alterations in NTRK genes attributable to colorectal cancer is below 0.5%."]], "type": "factoid", "id": "65f77397c4010b4d78000025", "snippets": [{"offsetInBeginSection": 975, "offsetInEndSection": 1154, "text": " In common cancers, rates were consistently below 0.5%. Rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers had higher rates.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36914665", "endSection": "abstract"}]}, {"body": "What are active ingredients of Trikafta?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36653239", "http://www.ncbi.nlm.nih.gov/pubmed/37503734", "http://www.ncbi.nlm.nih.gov/pubmed/37222401", "http://www.ncbi.nlm.nih.gov/pubmed/36831163"], "ideal_answer": "The active ingredients of Trikafta are elexacaftor, tezacaftor, and ivacaftor.", "exact_answer": [["ivacaftor"], ["tezacaftor"], ["elexacaftor"]], "type": "list", "id": "65d137871930410b1300003e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "The combination of CFTR modulators ivacaftor, tezacaftor and elexacaftor (Trikafta\u00ae, Kaftrio\u00ae) significantly improve outcomes, including survival in a broad range of cystic fibrosis patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36653239", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 295, "text": "CONTEXT: Elexacaftor/Tezacaftor/Ivacaftor (ETI; Trikafta\u2122) enhances aberrant cystic fibrosis transmembrane conductance regulator (CFTR) function and may improve the insulin secretory defects associated with a deterioration in clinical outcomes in pancreatic insufficient cystic fibrosis (PI-CF).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37503734", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 237, "text": "INTRODUCTION: A triple combination of CFTR modulators ELE/TEZ/IVA (elexacaftor/tezacaftor/ivacaftor, Trikafta\u2122) has been evaluated in clinical trials for people with cystic fibrosis (pwCF) and was approved to the European and US market. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222401", "endSection": "abstract"}, {"offsetInBeginSection": 1128, "offsetInEndSection": 1408, "text": "The method has been validated following international (EMA) guidelines for bioanalytical method validation and has been tested on plasma samples from 62 CF patients treated with the three-drug combination IVA/TEZ/ELX, marketed as Kaftrio\u00ae or Trikafta\u00ae, in steady-state condition. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36831163", "endSection": "abstract"}]}, {"body": "When was Havana Syndrome first recognized?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37965360", "http://www.ncbi.nlm.nih.gov/pubmed/35962646", "http://www.ncbi.nlm.nih.gov/pubmed/37976420"], "ideal_answer": "Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.", "exact_answer": [["Havana Syndrome was first recognized in 2016."]], "type": "factoid", "id": "65f856a1c4010b4d7800004e", "snippets": [{"offsetInBeginSection": 13, "offsetInEndSection": 206, "text": " In 2016 diplomatic personnel serving in Havana, Cuba, began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37965360", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 268, "text": "Since 2016, numerous American and Canadian diplomats and secret (intelligence) agents in Cuba, China, and other places in the world have experienced an abrupt onset of unusual clinical symptoms including, tinnitus, visual problems, vertigo, and cognitive difficulties,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35962646", "endSection": "abstract"}, {"offsetInBeginSection": 268, "offsetInEndSection": 438, "text": "This fact was illustrated in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37976420", "endSection": "abstract"}]}, {"body": "Is GC1118 effective for glioblastoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37537946"], "ideal_answer": "The effectiveness of GC1118 for glioblastoma is not supported by the study's primary endpoint (PFS6). However, the study did find that immune signatures were significantly upregulated in tumors with regression upon GC1118 therapy, suggesting the potential for immune-mediated antitumor efficacy. Further research is needed to determine the overall effectiveness of GC1118 for glioblastoma.", "exact_answer": "yes", "type": "yesno", "id": "65d131451930410b13000034", "snippets": [{"offsetInBeginSection": 1455, "offsetInEndSection": 1721, "text": "CONCLUSION: This study did not meet the primary endpoint (PFS6); however, we found that immune signatures were significantly upregulated in the tumors with regression upon GC1118 therapy, which signifies the potential of immune-mediated antitumor efficacy of GC1118.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37537946", "endSection": "abstract"}]}, {"body": "Can syphilis cause proctitis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36703251", "http://www.ncbi.nlm.nih.gov/pubmed/37267792", "http://www.ncbi.nlm.nih.gov/pubmed/35969837"], "ideal_answer": "Yes, syphilis can cause proctitis. Proctitis refers to inflammation of the rectum, and it can be caused by various infectious agents, including syphilis. In a case report, severe syphilitic proctitis led to large bowel obstruction, mimicking locally advanced rectal cancer. It is important to have a high degree of clinical suspicion to accurately identify syphilis as the cause of proctitis.", "exact_answer": "yes", "type": "yesno", "id": "65cfd13f1930410b1300001d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "A 26-year-old man in Australia who has sex with men had severe perianal ulceration, proctitis, and skin lesions develop. Testing revealed primary syphilis, mpox, and primary HIV infection. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36703251", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Syphilitic proctitis presenting as locally advanced rectal cancer: A case report.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37267792", "endSection": "title"}, {"offsetInBeginSection": 101, "offsetInEndSection": 248, "text": "We present a case of severe syphilitic proctitis leading to large bowel obstruction with imaging findings mimicking locally advanced rectal cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37267792", "endSection": "abstract"}, {"offsetInBeginSection": 1513, "offsetInEndSection": 1715, "text": "CONCLUSION: Severe proctitis leading to large bowel obstruction is a possible presentation of syphilis, and a high degree of clinical suspicion is necessary to be able to accurately identify the cause. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37267792", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 376, "text": "ABSTRACT: We analyzed microbiologic etiologies of proctitis among patients seen in an urban sexual health clinic during 2011 to 2021. Among 759 cases, 179 (24%) tested positive for Neisseria gonorrhoeae , 171 (23%) for Chlamydia trachomatis , 21 (3%) for herpes simplex virus, 30 (4%) for syphilis, and 73 (10%) for multiple pathogens; no pathogen was identified in 425 (56%).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35969837", "endSection": "abstract"}]}, {"body": "List the most effective treatment methods for Madelung disease.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37060787", "http://www.ncbi.nlm.nih.gov/pubmed/37363562", "http://www.ncbi.nlm.nih.gov/pubmed/21813877"], "ideal_answer": "The most effective treatment methods for Madelung disease include surgical resection of adipose tissue or liposuction, which are considered the mainstream treatments. However, the choice of treatment depends on factors such as the location of the fat, the size of the tumors, and the presence of important organs in the surrounding region. In some cases, an open surgical approach may be necessary to achieve good results. It is important to note that there is currently no consensus on the optimal treatment approach for Madelung disease.", "exact_answer": [["Surgical resection of adipose tissue"], ["Liposuction"]], "type": "list", "id": "65f377d5c4010b4d78000009", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 484, "text": "Madelung disease (MD) was first described by Brodie in 1846 as a rare multiple lipoma. It is a benign tumor characterized by symmetrical diffuse adipose tissue deposition in the proximal extremities and neck. Until now, the etiology and pathogenesis of the disease have not been fully explained, resulting in difficulties in diagnosis and treatment; moreover, palliative treatment, such as surgical resection of adipose tissue or liposuction, is still the mainstream treatment for MD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37060787", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 331, "text": "Madelung's disease is a rare disfiguring disorder that affects both function and esthetic appearance in the head and/or shoulder, neck, and arms regions. Lipectomy is typically necessary but such treatment can encounter difficulties due to the large sizes of the tumors, interspersed with important organs in the surrounding region", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37363562", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 689, "text": "Benign symmetrical lipomatosis (Madelung disease) is a rare metabolic disorder characterized by the presence of multiple, symmetric, nonencapsulated fat masses in the face, neck, and shoulders. The clinical course is slow, typically one of slow progressive enlargement with cosmetic and functional sequelae. The authors describe a case in which an open surgical approach was performed to treat this disorder, with good results. There are many aspects of treatment currently lacking a consensus, and the authors discuss these, principally in relation to the location of the fat, the role of liposuction versus surgery, the staging of surgical procedures, and the placement of the incisions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21813877", "endSection": "abstract"}]}, {"body": "What are active ingredients of Paxlovid?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37839266", "http://www.ncbi.nlm.nih.gov/pubmed/36703601", "http://www.ncbi.nlm.nih.gov/pubmed/36568522"], "ideal_answer": "The active ingredients of Paxlovid are nirmatrelvir and ritonavir.", "exact_answer": [["nirmatrelvir"], ["ritonavir"]], "type": "list", "id": "65d136bc1930410b1300003c", "snippets": [{"offsetInBeginSection": 147, "offsetInEndSection": 214, "text": " Paxlovid\u00ae is composed of two tablets, nirmatrelvir and ritonavir. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37839266", "endSection": "abstract"}, {"offsetInBeginSection": 580, "offsetInEndSection": 783, "text": "The anti-COVID drugs explored via other approaches include nirmatrelvir (used in combination with ritonavir as Paxlovid), tixagevimab and cilgavimab (both used in combination with each other) and others.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36703601", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36568522", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Introduction: Oral administration of ritonavir-boosted nirmatrelvir (Paxlovid) was found to be promising in the treatment of coronavirus disease 2019. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36568522", "endSection": "abstract"}]}, {"body": "What does capnography measure?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37507472", "http://www.ncbi.nlm.nih.gov/pubmed/37259022"], "ideal_answer": "Capnography measures the end-tidal carbon dioxide (CO2) concentration in exhaled breath. It provides a non-invasive and continuous assessment of ventilation and can detect abnormal ventilation or apnea early during cardiopulmonary resuscitation.", "exact_answer": [["Capnography measures end-tidal carbon dioxide concentrations."]], "type": "factoid", "id": "65f38059c4010b4d7800000e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "A secondary analysis of a randomized study was performed to study the relationship between volumetric capnography (VCAP) and arterial CO2 partial pressure (PCO2) during cardiopulmonary resuscitation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37507472", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 140, "text": " By continually monitoring end-tidal carbon dioxide concentrations, capnography can detect abnormal ventilation or apnoea early. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37259022", "endSection": "abstract"}]}, {"body": "Methotrexate is an antifolate medication.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36946211", "http://www.ncbi.nlm.nih.gov/pubmed/36508886"], "ideal_answer": "Yes, Methotrexate is an antifolate medication. It works by inhibiting the enzyme dihydrofolate reductase, which is involved in the synthesis of DNA, RNA, and proteins. By blocking this enzyme, Methotrexate interferes with the production of folate, a necessary component for cell division and growth. This mechanism of action makes Methotrexate effective in treating various conditions, including cancer, autoimmune diseases, and ectopic pregnancies.", "exact_answer": "yes", "type": "yesno", "id": "65f82fe1c4010b4d7800003f", "snippets": [{"offsetInBeginSection": 14, "offsetInEndSection": 49, "text": "Methotrexate (MTX) is an antifolate", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36946211", "endSection": "abstract"}, {"offsetInBeginSection": 662, "offsetInEndSection": 706, "text": "antifolate medications, such as methotrexate", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36508886", "endSection": "abstract"}]}, {"body": "What are the transmission mechanisms of the human Ebola infection?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33080902", "http://www.ncbi.nlm.nih.gov/pubmed/30513823", "http://www.ncbi.nlm.nih.gov/pubmed/30381349", "http://www.ncbi.nlm.nih.gov/pubmed/25719678"], "ideal_answer": "The transmission mechanisms of human Ebola infection include contact with infected bodily fluids such as blood, semen, saliva, urine, and breast milk. Human-to-human transmission can occur through direct contact with these fluids. There have been reports of sexual transmission from Ebola virus disease (EVD) survivors. Additionally, nosocomial transmission can occur in healthcare settings. It is important to isolate ill patients and practice hygienic burial of dead bodies to prevent further transmission. In areas where access to Ebola Treatment Units (ETUs) is limited, no-touch treatment should be provided to patients in their villages.", "exact_answer": [["Contact with infected bodily fluids"], ["Sexual transmission from EVD survivors"], ["Nosocomial transmission"], ["Transmission through hygienic burial of dead bodies"], ["No-touch treatment in the village of patients unwilling or unable to seek care at an ETU"]], "type": "list", "id": "65f84535c4010b4d78000044", "snippets": [{"offsetInBeginSection": 625, "offsetInEndSection": 774, "text": "multiple entry mechanisms, susceptibility of the host cells, employment of multiple immune evasion mechanisms and rapid person-to-person transmission", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33080902", "endSection": "abstract"}, {"offsetInBeginSection": 233, "offsetInEndSection": 424, "text": "EBOV has been described to occur via contact with infected bodily fluids, supported by data indicating that infectious EBOV could be cultured from blood, semen, saliva, urine, and breast milk", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30381349", "endSection": "abstract"}, {"offsetInBeginSection": 257, "offsetInEndSection": 284, "text": "human-to-human transmission", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30513823", "endSection": "abstract"}, {"offsetInBeginSection": 360, "offsetInEndSection": 438, "text": "persistent EBOV infections and included sexual transmission from EVD survivors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30513823", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 511, "text": "Asymptomatic infection and long-term viral persistence in EVD survivors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30513823", "endSection": "abstract"}, {"offsetInBeginSection": 686, "offsetInEndSection": 756, "text": "persistence of filoviruses and their potential for sexual transmission", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30513823", "endSection": "abstract"}, {"offsetInBeginSection": 273, "offsetInEndSection": 296, "text": "nosocomial transmission", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26910462", "endSection": "abstract"}, {"offsetInBeginSection": 1078, "offsetInEndSection": 1115, "text": "importance of isolating ill patients ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25719678", "endSection": "abstract"}, {"offsetInBeginSection": 1460, "offsetInEndSection": 1490, "text": "hygienic burial of dead bodies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25719678", "endSection": "abstract"}, {"offsetInBeginSection": 1559, "offsetInEndSection": 1647, "text": "no-touch treatment in the village of patients unwilling or unable to seek care at an ETU", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25719678", "endSection": "abstract"}]}, {"body": "Gantenerumab was developed for treatment of which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35841240", "http://www.ncbi.nlm.nih.gov/pubmed/36447240", "http://www.ncbi.nlm.nih.gov/pubmed/37017737", "http://www.ncbi.nlm.nih.gov/pubmed/36751779", "http://www.ncbi.nlm.nih.gov/pubmed/36281062", "http://www.ncbi.nlm.nih.gov/pubmed/36515320", "http://www.ncbi.nlm.nih.gov/pubmed/36388611"], "ideal_answer": "Gantenerumab was developed for the treatment of early symptomatic and asymptomatic Alzheimer's disease (AD).", "exact_answer": [["Gantenerumab was developed for the treatment of early symptomatic and asymptomatic Alzheimer's disease (AD)."]], "type": "factoid", "id": "65cfa37c1930410b1300000d", "snippets": [{"offsetInBeginSection": 259, "offsetInEndSection": 442, "text": "Other anti-amyloid antibodies are under investigation in phase III (donanemab, lecanemab, gantenerumab) and have shown preliminary evidence of a cognitive benefit in phase II trials. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35841240", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36447240", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "BACKGROUND: This review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development to treat early symptomatic and asymptomatic Alzheimer's disease (AD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36447240", "endSection": "abstract"}, {"offsetInBeginSection": 1026, "offsetInEndSection": 1157, "text": "BODY: Here, we review over 2 decades of gantenerumab development in the context of scientific discoveries in the broader AD field. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36447240", "endSection": "abstract"}, {"offsetInBeginSection": 1666, "offsetInEndSection": 1865, "text": "CONCLUSION: The results from the gantenerumab phase 3 programs are expected by the end of 2022 and will add critical information to the collective knowledge on the search for effective AD treatments.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36447240", "endSection": "abstract"}, {"offsetInBeginSection": 604, "offsetInEndSection": 901, "text": "METHODS: Sixty-six mutation-positive participants enrolled in the gantenerumab and placebo arms of the first Dominantly Inherited Alzheimer Network Trials Unit clinical trial (DIAN-TU-001) underwent both 11C-PiB and 18F-florbetapir PET imaging at baseline and during at least one follow-up visit. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37017737", "endSection": "abstract"}, {"offsetInBeginSection": 543, "offsetInEndSection": 847, "text": "Two long-term, controlled trials on three anti-\u03b2-amyloid monoclonal antibodies (solanezumab, gantenerumab and crenezumab) in subjects carrying Alzheimer's disease-linked mutated genes encoding for amyloid precursor protein or presenilin 1 or presenilin 2 failed to show cognitive or functional benefits. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36751779", "endSection": "abstract"}, {"offsetInBeginSection": 776, "offsetInEndSection": 1062, "text": "The model components were calibrated to data from the literature and internal studies, including quantitative data supporting the underlying AD biology and clinical data from clinical trials for anti-A\u03b2 monoclonal antibodies (mAbs) aducanumab, crenezumab, gantenerumab, and solanezumab.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36281062", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 573, "text": "INTRODUCTION: Recent published clinical trial safety data showed that 41% of Alzheimer patients experienced amyloid-related imaging abnormalities (ARIA), marks of microhemorrhages and edema in the brain, following administration of Biogen's Aduhelm/aducanumab (amino acids 3-7 of the A\u03b2 peptide). Similarly, Janssen/Pfizer's Bapineuzumab (amino acids 1-5 of the A\u03b2 peptide) and Roche's Gantenerumab (amino acids 2-11/18-27 of the A\u03b2 peptide) also displayed ARIA in clinical trials, including microhemorrhage and focal areas of inflammation or vasogenic edema, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36515320", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 332, "text": "Patients with Alzheimer's disease who have been given monoclonal antibodies targeting amyloid-\u03b2 (A\u03b2) (eg, gantenerumab, donanemab, lecanemab, and aducanumab) for scientific purposes may have a spectrum of imaging findings known as amyloid-related imaging abnormalities (ARIA), shown on brain magnetic resonance imaging (MRI) scans. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36388611", "endSection": "abstract"}]}, {"body": "What is the administration route of zavegepant?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37345774", "http://www.ncbi.nlm.nih.gov/pubmed/37038933", "http://www.ncbi.nlm.nih.gov/pubmed/37227596", "http://www.ncbi.nlm.nih.gov/pubmed/36804093"], "ideal_answer": "Zavegepant is administered intranasally as a nasal spray.", "exact_answer": [["Zavegepant is administered intranasally."]], "type": "factoid", "id": "65d1357c1930410b13000039", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Zavegepant (Zavzpret), a nasal spray, is approved to treat adults with acute migraine with or without aura.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37345774", "endSection": "abstract"}, {"offsetInBeginSection": 405, "offsetInEndSection": 658, "text": "Ubrogepant is ratified for acute migraine treatment, atogepant is validated for preventive therapy, whereas rimegepant is ratified for both indications, all via oral administration and while zavegepant is administered intranasally for migraine attacks. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37038933", "endSection": "abstract"}, {"offsetInBeginSection": 246, "offsetInEndSection": 403, "text": "In March 2023, zavegepant nasal spray (ZAVZPRET\u2122) received its first approval in the USA for the acute treatment of migraine with or without aura in adults. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37227596", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36804093", "endSection": "title"}, {"offsetInBeginSection": 187, "offsetInEndSection": 349, "text": "Zavegepant, an intranasally administered small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, was previously assessed in a phase 2/3 trial. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36804093", "endSection": "abstract"}, {"offsetInBeginSection": 2868, "offsetInEndSection": 3015, "text": "INTERPRETATION: Zavegepant 10 mg nasal spray was efficacious in the acute treatment of migraine, with favourable tolerability and safety profiles. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36804093", "endSection": "abstract"}]}, {"body": "What is the relationship between  Electroporation (EP) and DNA vaccines?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36992261", "http://www.ncbi.nlm.nih.gov/pubmed/38063059"], "ideal_answer": "Electroporation (EP) is a technique used to enhance the immunogenicity of DNA vaccines. It involves the application of electrical pulses to cells or tissues, which creates temporary pores in the cell membrane, allowing for increased uptake of the DNA vaccine. This increased uptake leads to improved delivery and expression of the vaccine antigen, resulting in a stronger immune response. Therefore, electroporation plays a crucial role in enhancing the effectiveness of DNA vaccines.", "exact_answer": [["Electroporation (EP) is a method used to enhance the immunogenicity of DNA vaccines."], ["It involves the application of electric pulses to cells or tissues, which creates temporary pores in the cell membrane."], ["These pores allow for increased uptake of the DNA vaccine and enhance its delivery to target cells."], ["The enhanced delivery of the DNA vaccine through electroporation results in improved immune responses and increased vaccine efficacy."]], "type": "factoid", "id": "65f494d7c4010b4d78000013", "snippets": [{"offsetInBeginSection": 182, "offsetInEndSection": 260, "text": "Electroporation (EP) is an effective way to increase the immunogenicity of DNA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/38063059", "endSection": "abstract"}, {"offsetInBeginSection": 228, "offsetInEndSection": 378, "text": "n this study, we challenged this concept by characterizing the immunological response induced by a plasmid DNA vaccine delivered using electroporation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36992261", "endSection": "abstract"}]}, {"body": "What disease can be treated with Tebentafusp?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37444540", "http://www.ncbi.nlm.nih.gov/pubmed/37483658", "http://www.ncbi.nlm.nih.gov/pubmed/36931146", "http://www.ncbi.nlm.nih.gov/pubmed/36970111", "http://www.ncbi.nlm.nih.gov/pubmed/36600005"], "ideal_answer": "Tebentafusp is approved for the treatment of metastatic uveal melanoma (mUM), a type of cancer that affects the eye.", "exact_answer": [["Metastatic uveal melanoma (mUM)"]], "type": "factoid", "id": "65cec1fb1930410b13000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37444540", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "BACKGROUND: Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to have survival benefits in a first-line setting.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37444540", "endSection": "abstract"}, {"offsetInBeginSection": 1140, "offsetInEndSection": 1254, "text": "Treatment with ICI followed by tebentafusp may result in longer PFS/OS compared to the inverse treatment sequence.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37444540", "endSection": "abstract"}, {"offsetInBeginSection": 322, "offsetInEndSection": 446, "text": "Tebentafusp, a bispecific molecule, has recently become the first treatment in decades to improve overall survival for mUM. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37483658", "endSection": "abstract"}, {"offsetInBeginSection": 2309, "offsetInEndSection": 2563, "text": "CONCLUSIONS: Tebentafusp achieved the best results compared to combined ICB and other systemic treatments, although these results have to be interpreted with caution due to the approximative methodical approach and high heterogeneity of included studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36931146", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36970111", "endSection": "title"}, {"offsetInBeginSection": 228, "offsetInEndSection": 460, "text": "Tebentafusp is both the first bispecific T-cell engager to show efficacy in the treatment of advanced solid cancer and the first anti-cancer treatment to demonstrate an overall survival benefit in patients with uveal melanoma (UM). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36970111", "endSection": "abstract"}, {"offsetInBeginSection": 881, "offsetInEndSection": 1065, "text": "These advances have driven the development of a number of novel emerging treatments, including tebentafusp, the first systemic therapy to achieve regulatory approval for this disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36600005", "endSection": "abstract"}]}, {"body": "What is the mechanisms of action of Dersimelagon?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37043653", "http://www.ncbi.nlm.nih.gov/pubmed/37060458", "http://www.ncbi.nlm.nih.gov/pubmed/37078227", "http://www.ncbi.nlm.nih.gov/pubmed/36840969"], "ideal_answer": "Dersimelagon is a selective melanocortin 1 receptor agonist. It works by activating the melanocortin 1 receptor, which increases levels of skin eumelanin.", "type": "summary", "id": "65d144731930410b13000040", "snippets": [{"offsetInBeginSection": 297, "offsetInEndSection": 422, "text": "Dersimelagon is a new, orally administered, selective melanocortin 1 receptor agonist that increases levels of skin eumelanin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37043653", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "PURPOSE: To describe outcomes from the first-in-human study of dersimelagon, an investigational oral selective MC1R agonist, under development for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37060458", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "Absorption, metabolism, and excretion of [14 C]dersimelagon, an investigational oral selective melanocortin 1 receptor agonist, in preclinical species and healthy volunteers.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37078227", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 292, "text": "Dersimelagon (formerly MT-7117) is a novel, orally administered nonpeptide small molecule selective agonist for melanocortin 1 receptor currently being investigated for the treatment of erythropoietic protoporphyria, X-linked protoporphyria, and diffuse cutaneous systemic sclerosis (dcSSc). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37078227", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "Dersimelagon is a novel orally administered selective agonist for melanocortin receptor 1 being investigated for the treatment of erythropoietic protoporphyria, X-linked protoporphyria, and diffuse cutaneous systemic sclerosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36840969", "endSection": "abstract"}]}, {"body": "What are the current indications for thalidomide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25617013", "http://www.ncbi.nlm.nih.gov/pubmed/21048383"], "ideal_answer": "Thalidomide is currently indicated for the management of various rheumatologic skin conditions, including lupus erythematosus, aphthous stomatitis, and chronic graft-versus-host disease in children. It is also used in the treatment of actinic prurigo and epidermolysis bullosa pruriginosa. Additionally, thalidomide is effective in managing erythema nodosum leprosum, aphthous ulceration, and cachexia in HIV disease, inflammatory bowel diseases, and certain malignant diseases.", "exact_answer": [["lupus erythematosus"], ["aphthous stomatitis"], ["chronic graft-versus-host disease in children"], ["actinic prurigo"], ["epidermolysis bullosa pruriginosa"]], "type": "list", "id": "65f82218c4010b4d7800003e", "snippets": [{"offsetInBeginSection": 231, "offsetInEndSection": 366, "text": "erythema nodosum leprosum, aphthous ulceration and cachexia in HIV disease, inflammatory bowel diseases, and several malignant diseases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21048383", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Thalidomide is resurging in the management of adult rheumatologic skin conditions, especially lupus erythematosus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25617013", "endSection": "abstract"}, {"offsetInBeginSection": 463, "offsetInEndSection": 532, "text": "aphthous stomatitis and chronic graft-versus-host disease in children", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25617013", "endSection": "abstract"}, {"offsetInBeginSection": 593, "offsetInEndSection": 646, "text": "actinic prurigo and epidermolysis bullosa pruriginosa", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25617013", "endSection": "abstract"}]}, {"body": "Do black race patients have worse survival in colorectal cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29146523", "http://www.ncbi.nlm.nih.gov/pubmed/24231453"], "ideal_answer": "Yes, studies have shown that black race patients with colorectal cancer have worse survival compared to white patients. In a study analyzing data from the National Cancer Database, it was found that black patients had a 9.2% lower 5-year survival rate compared to white patients. However, when adjusting for patient, tumor, and demographic variables, the risk of death was marginally reduced. Furthermore, after accounting for differences in treatment, the increased risk of death for black patients disappeared. Insurance coverage differences were found to account for approximately half of the survival rate disparity between black and white patients with colorectal cancer.", "exact_answer": "yes", "type": "yesno", "id": "65f77236c4010b4d7800001f", "snippets": [{"offsetInBeginSection": 1189, "offsetInEndSection": 1356, "text": "The absolute 5-year survival difference between black and white unmatched patients with CRC was 9.2% (57.3% for black patients vs 66.5% for\u00a0white patients; P\u00a0<\u00a0.0001).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29146523", "endSection": "abstract"}, {"offsetInBeginSection": 1068, "offsetInEndSection": 1507, "text": "Unadjusted survival analysis found a 15% higher chance of dying for black patients compared with white patients (hazard ratio [HR] = 1.15; 95% confidence interval (CI) = 1.08 to 1.22; P < .001). Adjustment for patient, tumor, and demographic variables marginally reduced the risk of death (HR = 1.08; 95% CI = 1.01 to 1.15; P = .03). After adjustment for differences in treatment, the increased risk of death for black patients disappeared", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24231453", "endSection": "abstract"}, {"offsetInBeginSection": 1944, "offsetInEndSection": 2171, "text": "In an analysis of data\u00a0from the National Cancer Database, we found that insurance coverage differences accounted for approximately one half of the disparity in survival rate of black vs white patients with CRC, 18-64 years old;", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29146523", "endSection": "abstract"}]}, {"body": "Is COACH syndrome a rare autosomal recessive genetic disease characterized by liver fibrosis and related to portal hypertension.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36617405", "http://www.ncbi.nlm.nih.gov/pubmed/37965976"], "ideal_answer": "Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis and is related to portal hypertension. The clinical features of COACH syndrome include cerebellar vermis hypoplasia, oligophrenia, ataxia, coloboma, and hepatic fibrosis. The liver fibrosis in COACH syndrome can lead to severe complications associated with portal hypertension.", "exact_answer": "yes", "type": "yesno", "id": "65f70d71c4010b4d7800001e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "The clinical features of cerebellar vermis hypoplasia, oligophrenia, ataxia, coloboma, and hepatic fibrosis (COACH) characterize the rare autosomal recessive multisystem disorder called COACH syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36617405", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 174, "text": "COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertension. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37965976", "endSection": "abstract"}]}, {"body": "Is Lecanemab approved for Alzheimer\u2019s Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37490245", "http://www.ncbi.nlm.nih.gov/pubmed/37389302", "http://www.ncbi.nlm.nih.gov/pubmed/37414156", "http://www.ncbi.nlm.nih.gov/pubmed/37334596", "http://www.ncbi.nlm.nih.gov/pubmed/37357276"], "ideal_answer": "Yes, Lecanemab (Leqembi\u00ae) is approved for the treatment of Alzheimer's Disease (AD) in the United States. It is indicated to be initiated in early AD, including mild cognitive impairment (MCI) due to AD or mild AD dementia, with confirmed brain amyloid pathology.", "exact_answer": "yes", "type": "yesno", "id": "65ce88b71930410b13000001", "snippets": [{"offsetInBeginSection": 819, "offsetInEndSection": 1069, "text": "Data from recent trials implicate these agents as the first effective disease-modifying therapies against AD and has led to the US Food and Drug Administration (FDA) recent approval of aducanumab and lecanemab, under an accelerated approval pathway. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37490245", "endSection": "abstract"}, {"offsetInBeginSection": 819, "offsetInEndSection": 1068, "text": "Data from recent trials implicate these agents as the first effective disease-modifying therapies against AD and has led to the US Food and Drug Administration (FDA) recent approval of aducanumab and lecanemab, under an accelerated approval pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37490245", "endSection": "abstract"}, {"offsetInBeginSection": 220, "offsetInEndSection": 462, "text": "At the time of writing, two amyloid-lowering antibodies, aducanumab and lecanemab, have obtained United States Food and Drug Administration accelerated approval, with further agents of this class in the Alzheimer's disease treatment pipeline.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37490245", "endSection": "abstract"}, {"offsetInBeginSection": 220, "offsetInEndSection": 461, "text": "At the time of writing, two amyloid-lowering antibodies, aducanumab and lecanemab, have obtained United States Food and Drug Administration accelerated approval, with further agents of this class in the Alzheimer's disease treatment pipeline", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37389302", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "The US Food and Drug Administration (FDA)'s recent accelerated approval of two anti-amyloid antibodies for treatment of Alzheimer's disease (AD), aducanumab and lecanemab, has caused substantial debate. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37414156", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "After the CLARITY-AD clinical trial results of lecanemab were interpreted as positive, and supporting the amyloid hypothesis, the drug received accelerated Food and Drug Administration approval.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37334596", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "Lecanemab (Leqembi\u00ae) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37357276", "endSection": "abstract"}]}, {"body": "What type of extracolonic tumors does the PMS2 germline mutation cause?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30161022"], "ideal_answer": "The PMS2 germline mutation is associated with an increased risk of colorectal and endometrial cancer in heterozygous carriers. However, it does not significantly increase the risk of any other Lynch syndrome-associated cancer.", "exact_answer": [["The PMS2 germline mutation is associated with an increased risk of colorectal and endometrial cancer in Lynch syndrome."]], "type": "factoid", "id": "65f7736fc4010b4d78000024", "snippets": [{"offsetInBeginSection": 1516, "offsetInEndSection": 1675, "text": "Heterozygous PMS2 mutation carriers were at small increased risk for colorectal and endometrial cancer but not for any other Lynch syndrome-associated cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/30161022", "endSection": "abstract"}]}, {"body": "What disorder is considered off label use for domperidone?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35793516", "http://www.ncbi.nlm.nih.gov/pubmed/37352416", "http://www.ncbi.nlm.nih.gov/pubmed/36367713"], "ideal_answer": "Domperidone is considered an off-label treatment for promoting lactation in prolactin-deficient women.", "exact_answer": [["Domperidone is considered off-label for inducing lactation in prolactin-deficient women."]], "type": "factoid", "id": "65f493cac4010b4d78000012", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 113, "text": "Domperidone is an antiemetic that is commonly used as an off-label prescription to induce lactation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35793516", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "Domperidone is a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary. It is prescribed off-label in Canada and Australia to promote lactation in prolactin-deficient women. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37352416", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 100, "text": "Domperidone is a dopamine-2 antagonist used off-label to increase breast milk production", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36367713", "endSection": "abstract"}]}, {"body": "Are Hemoglobin-Based Oxygen Carriers approved for human use?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36837597", "http://www.ncbi.nlm.nih.gov/pubmed/34776270"], "ideal_answer": "No, Hemoglobin-Based Oxygen Carriers (HBOCs) have not been approved for human use by the FDA and EMA, except for compassionate use. However, HBOCs have been approved for veterinary use in the European Union and the United States, and they are also being used for organ preservation in organ transplantation in the European Union. Some HBOCs are still undergoing active clinical studies.", "exact_answer": "no", "type": "yesno", "id": "65f84b5ec4010b4d78000048", "snippets": [{"offsetInBeginSection": 118, "offsetInEndSection": 257, "text": "As of today, there is no widely accepted product used as an alternative to human blood in clinical settings with severe anemic condition(s)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597", "endSection": "abstract"}, {"offsetInBeginSection": 504, "offsetInEndSection": 598, "text": "products still in active clinical research in the category of hemoglobin-based oxygen carriers", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597", "endSection": "abstract"}, {"offsetInBeginSection": 739, "offsetInEndSection": 1027, "text": "Hemopure is in clinical use in South Africa and Russia. Oxyglobin, the sister product of Hemopure, has been approved for veterinary use in the European Union and the United States. HemO2life has recently been approved for organ preservation in organ transplantation in the European Union.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597", "endSection": "abstract"}, {"offsetInBeginSection": 1028, "offsetInEndSection": 1096, "text": "OxyVita and Sanguinate are still undergoing active clinical studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597", "endSection": "abstract"}, {"offsetInBeginSection": 1301, "offsetInEndSection": 1395, "text": "Unfortunately, so far, no HBOC has been approved by FDA and EMA, except for compassionate use.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34776270", "endSection": "abstract"}, {"offsetInBeginSection": 1536, "offsetInEndSection": 1624, "text": "HBOCs \"repositioning\" has led to their successful application in organ perfusion fluids.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34776270", "endSection": "abstract"}]}, {"body": "Do stroke patients have a lower risk of Obstructive Sleep Apnea?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37443640", "http://www.ncbi.nlm.nih.gov/pubmed/36889030"], "ideal_answer": "No, stroke patients actually have a higher risk of developing obstructive sleep apnea (OSA). Sleep disturbances, including OSA, are highly prevalent after stroke and are considered to be a risk factor for poor post-stroke outcomes. The relationship between sleep and stroke is complex, with sleep disturbances likely both contributing to and being a consequence of stroke.", "exact_answer": "no", "type": "yesno", "id": "65f7080fc4010b4d78000019", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Sleep-Disordered Breathing and Prognosis after Ischemic Stroke: It Is Not Apnea-Hypopnea Index That Matters.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37443640", "endSection": "title"}, {"offsetInBeginSection": 11, "offsetInEndSection": 147, "text": " Sleep-disordered breathing (SDB) is highly prevalent after stroke and is considered to be a risk factor for poor post-stroke outcomes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37443640", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Post-stroke sleep disturbance and recurrent cardiovascular and cerebrovascular events: A systematic review and meta-analysis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36889030", "endSection": "title"}, {"offsetInBeginSection": 204, "offsetInEndSection": 339, "text": "The relationship between sleep and stroke is complex: sleep disturbances are likely both a contributor to, and consequence of, stroke. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36889030", "endSection": "abstract"}]}, {"body": "Should we treat all patients with glaucoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36564597", "http://www.ncbi.nlm.nih.gov/pubmed/36307903", "http://www.ncbi.nlm.nih.gov/pubmed/33433580", "http://www.ncbi.nlm.nih.gov/pubmed/35647957"], "ideal_answer": "Not all patients with glaucoma require treatment. The decision to treat depends on various factors such as the severity of the disease, the presence of symptoms, the rate of progression, and the patient's overall health. Treatment is typically recommended for patients with progressive glaucoma, significant visual field loss, or high intraocular pressure that puts them at risk for further damage. However, the management approach should be individualized, and the benefits and risks of treatment should be carefully considered in each case.", "exact_answer": "no", "type": "yesno", "id": "65f85f77c4010b4d78000053", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 175, "text": "Trans-scleral diode laser cycloablation (cyclodiode) is effective in the short-term management of refractory glaucoma where alternative treatments are not feasible", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36307903", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 155, "text": "Glaucoma is the most common cause of irreversible blindness worldwide. Many patients with glaucoma are asymptomatic early in the disease course", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433580", "endSection": "abstract"}, {"offsetInBeginSection": 157, "offsetInEndSection": 306, "text": "Primary care clinicians should know which patients to refer to an eye care professional for a complete eye examination to check for signs of glaucoma", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433580", "endSection": "abstract"}, {"offsetInBeginSection": 596, "offsetInEndSection": 785, "text": "Glaucoma is a chronic progressive optic neuropathy, characterized by damage to the optic nerve and retinal nerve fiber layer, that can lead to permanent loss of peripheral or central vision", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433580", "endSection": "abstract"}, {"offsetInBeginSection": 1373, "offsetInEndSection": 1553, "text": " Treatment of glaucoma involves lowering intraocular pressure. This can be achieved with various classes of glaucoma medications as well as laser and incisional surgical procedures", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433580", "endSection": "abstract"}, {"offsetInBeginSection": 1581, "offsetInEndSection": 1792, "text": "Vision loss from glaucoma can be minimized by recognizing systemic conditions and medications that increase a patient's risk of glaucoma and referring high-risk patients for a complete ophthalmologic examination", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433580", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 53, "text": "irreversible vision loss from Glaucoma ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35647957", "endSection": "abstract"}, {"offsetInBeginSection": 127, "offsetInEndSection": 235, "text": "intraocular pressure (IOP) is the only modifiable risk factor identified to prevent glaucomatous vision loss", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35647957", "endSection": "abstract"}, {"offsetInBeginSection": 237, "offsetInEndSection": 315, "text": "Medical management remains the first-line of treatment in most adult glaucomas", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35647957", "endSection": "abstract"}]}, {"body": "What is IL-35?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36731088", "http://www.ncbi.nlm.nih.gov/pubmed/36579639", "http://www.ncbi.nlm.nih.gov/pubmed/37464473", "http://www.ncbi.nlm.nih.gov/pubmed/36314719"], "ideal_answer": "IL-35 is a cytokine that is involved in immunosuppression. It is secreted by regulatory T cells (Treg) and B cells. IL-35 mediates immunosuppression of T cells in autoimmune diseases.", "type": "summary", "id": "65f5a319c4010b4d78000016", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "INTERLEUKIN-35 DOWNREGULATES THE IMMUNE RESPONSE OF EFFECTOR CD4 + T CELLS VIA RESTRICTING HIGH MOBILITY GROUP BOX-1 PROTEIN-DEPENDENT AUTOPHAGY IN SEPSIS.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36731088", "endSection": "title"}, {"offsetInBeginSection": 138, "offsetInEndSection": 216, "text": "The novel role of the anti-inflammatory cytokine IL-35 in sepsis was examined.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36731088", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 157, "text": "Interleukin 35 (IL-35) is involved in the pathogenesis of endometriosis by suppressing immunoreaction and promoting endometrial cell proliferation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36579639", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 161, "text": "Interleukin-35 (IL-35), secreted by regulatory T cells (Treg) and B cells, is immunosuppressive under both physiological and pathological conditions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37464473", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Interleukin 35 (IL-35) mediates immunosuppression of T cells in autoimmune diseases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36314719", "endSection": "abstract"}]}, {"body": "What is the cause of Leigh syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18651330", "http://www.ncbi.nlm.nih.gov/pubmed/8338207"], "ideal_answer": "Leigh syndrome can result from various defects in mitochondrial enzyme complexes, including pyruvate dehydrogenase complex deficiency, respiratory chain complexes I, II, III, IV, and V deficiencies. Specifically, it can be caused by defects in pyruvate dehydrogenase complex, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the NARP point mutation.", "exact_answer": [["Leigh syndrome can result from several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V."]], "type": "factoid", "id": "6451007857b1c7a315000093", "snippets": [{"offsetInBeginSection": 281, "offsetInEndSection": 443, "text": "It may result from several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18651330", "endSection": "abstract"}, {"offsetInBeginSection": 2788, "offsetInEndSection": 3040, "text": "Leigh syndrome may result from different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the recently described NARP point mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8338207", "endSection": "abstract"}]}, {"body": "What is the main cause of spillover events?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37019573", "http://www.ncbi.nlm.nih.gov/pubmed/29466832"], "ideal_answer": "The main cause of spillover events is the transmission of pathogens from wildlife to domestic animals and humans. This transmission can occur through direct contact, consumption of contaminated food or water, or exposure to contaminated environments. Habitat loss and fragmentation play a significant role in increasing the risk of spillover events, as it brings wildlife and humans into closer proximity, facilitating the transmission of pathogens.", "exact_answer": [["The main cause of spillover events is the transmission of pathogens from wildlife to domestic animals and humans."]], "type": "factoid", "id": "65f8447fc4010b4d78000043", "snippets": [{"offsetInBeginSection": 925, "offsetInEndSection": 1161, "text": "the extent of land use for food production and the agricultural practices employed that shape four archetypal food systems, each with a distinct risk profile with respect to zoonotic spillovers and differing dimensions of sustainability", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37019573", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Pathogen spillover from wildlife to domestic animals and humans", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29466832", "endSection": "abstract"}, {"offsetInBeginSection": 579, "offsetInEndSection": 651, "text": "the highest spillover risk occurs at intermediate levels of habitat loss", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29466832", "endSection": "abstract"}]}, {"body": "is carotenodermia caused by an excess of lycopene in the diet?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37916485", "http://www.ncbi.nlm.nih.gov/pubmed/3421202", "http://www.ncbi.nlm.nih.gov/pubmed/3434946"], "ideal_answer": "No, carotenodermia is not caused by an excess of lycopene in the diet. It is caused by an excess intake of carotenoids, including beta-carotene, which can lead to the deposition of carotene in the skin, resulting in a yellow to orange discoloration.", "exact_answer": "no", "type": "yesno", "id": "65ef83acdffffb9b6b000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Carotenodermia is a yellow to orange skin discoloration due to epidermal deposition of carotene. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37916485", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "We evaluated the relation between plasma levels of carotenoids and carotenodermia in 30 men receiving carotenoid supplementation for 42 d", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3421202", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Four cases of carotenodermia are presented, secondary to marked ingestion of carotenoid-rich vegetables.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3434946", "endSection": "abstract"}]}, {"body": "What type of DMD can golodirsen be used for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32026421"], "ideal_answer": "Golodirsen can be used for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.", "exact_answer": [["Golodirsen can be used for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping."]], "type": "factoid", "id": "64179034690f196b5100002b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Golodirsen (Vyondys 53\u2122), an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass designed to induce exon 53 skipping", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32026421", "endSection": "abstract"}, {"offsetInBeginSection": 251, "offsetInEndSection": 455, "text": "In December 2019, intravenous golodirsen received its first global approval in the USA for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32026421", "endSection": "abstract"}]}, {"body": "What is the indication for Alirocumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35052871", "http://www.ncbi.nlm.nih.gov/pubmed/27250613"], "ideal_answer": "The indication for Alirocumab is to reduce LDL cholesterol levels in patients who have not achieved their target LDL cholesterol levels with maximally tolerated statin therapy or in patients who are intolerant to statins.", "exact_answer": [["Alirocumab is indicated for the treatment of high LDL cholesterol levels."]], "type": "factoid", "id": "65f70b9cc4010b4d7800001c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 49, "text": "Effects of Alirocumab on Triglyceride Metabolism:", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052871", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 290, "text": "PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9 antibodies on triglyceride metabolism are less pronounced. The present study aimed to investigate in detail the effects of alirocumab on triglycerides, triglyceride-rich lipoproteins, and lipase regulators.M", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052871", "endSection": "abstract"}, {"offsetInBeginSection": 290, "offsetInEndSection": 602, "text": "To achieve target LDL-cholesterol in these two groups of patients will be possible with new drugs - PCSK9 inhibitors, which decrease LDL-cholesterol by an additional 50-60 %. The first two PCSK9 inhibitors (alirocumab and evolocumab) already had been approved for clinical use by European regulatory authorities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27250613", "endSection": "abstract"}]}, {"body": "Concizumab is used for which diseases?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37341887", "http://www.ncbi.nlm.nih.gov/pubmed/35869698", "http://www.ncbi.nlm.nih.gov/pubmed/37146647", "http://www.ncbi.nlm.nih.gov/pubmed/37646676"], "ideal_answer": "Concizumab is used for the treatment of hemophilia A and B with and without inhibitors.", "exact_answer": [["hemophilia A"], ["hemophilia B"]], "type": "list", "id": "65cfad2d1930410b13000014", "snippets": [{"offsetInBeginSection": 226, "offsetInEndSection": 599, "text": "Concizumab is being developed by Novo Nordisk for the treatment of hemophilia A and B with and without inhibitors. In March 2023, concizumab was approved in Canada for the treatment of adolescent and adult patients (12 years of age or older) with hemophilia B who have FIX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37341887", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 285, "text": "Some non-factor products that work by facilitating the coagulation pathway (emicizumab) and blocking the anticoagulant pathway (fitusiran, concizumab and marstacimab) for patients with haemophilia (H) have been developed, and clinical trials using these products are currently ongoing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35869698", "endSection": "abstract"}, {"offsetInBeginSection": 176, "offsetInEndSection": 299, "text": "A previous trial of concizumab (explorer4) established proof of concept in patients with hemophilia A or B with inhibitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646676", "endSection": "abstract"}]}, {"body": "What is DEXTR", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34920276"], "ideal_answer": "DEXTR is a semi-automated data extraction tool designed for literature-based reviews in the field of environmental health sciences. It aims to address data-extraction challenges by providing a simple user interface, incorporating user verification and entity connecting capabilities, and facilitating further automation developments.", "type": "summary", "id": "65f37871c4010b4d7800000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Evaluation of a semi-automated data extraction tool for public health literature-based reviews: Dextr.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34920276", "endSection": "title"}, {"offsetInBeginSection": 1876, "offsetInEndSection": 2247, "text": "The Dextr tool addresses data-extraction challenges associated with environmental health sciences literature with a simple user interface, incorporates the key capabilities of user verification and entity connecting, provides a platform for further automation developments, and has the potential to improve data extraction for literature reviews in this and other fields.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/34920276", "endSection": "abstract"}]}, {"body": "Is measles immunisation the best public health approach to reduce incidence of measles worldwide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36680212", "http://www.ncbi.nlm.nih.gov/pubmed/37971951"], "ideal_answer": "Yes, measles immunization is the best public health approach to reduce the incidence of measles worldwide. The administration of two doses of measles vaccines is the most effective strategy to prevent and eliminate measles. Vaccination has been proven to avert millions of measles deaths and prevent outbreaks. Strengthening surveillance and renewing efforts to vaccinate all children with two doses of the measles vaccine are crucial steps in preventing outbreaks and accelerating progress toward measles elimination.", "exact_answer": "yes", "type": "yesno", "id": "65f84d20c4010b4d7800004a", "snippets": [{"offsetInBeginSection": 1540, "offsetInEndSection": 1713, "text": "renewing efforts to vaccinate all children with 2 MCV doses and strengthening surveillance, thereby preventing outbreaks and accelerating progress toward measles elimination", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971951", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Measles is a highly contagious, vaccine-preventable disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971951", "endSection": "abstract"}, {"offsetInBeginSection": 1087, "offsetInEndSection": 1170, "text": "an estimated 57 million measles deaths were averted by vaccination during 2000-2022", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971951", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Measles is a highly contagious, but vaccine-preventable disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36680212", "endSection": "abstract"}, {"offsetInBeginSection": 108, "offsetInEndSection": 223, "text": "the administration of two doses of measles vaccines is the most effective strategy to prevent and eliminate measles", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36680212", "endSection": "abstract"}]}, {"body": "What types of glucosteroids are used for the management of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35713895", "http://www.ncbi.nlm.nih.gov/pubmed/35723111", "http://www.ncbi.nlm.nih.gov/pubmed/35073949"], "ideal_answer": "The types of glucocorticoids used for the management of Duchenne muscular dystrophy (DMD) are prednisone, prednisolone, and deflazacort. These steroids help to reduce muscle inflammation and are considered the current standard of care for patients with DMD. Specifically, deflazacort and prednisone/prednisolone have been shown to improve muscle strength, timed motor function, pulmonary function, delay loss of ambulation, delay onset of cardiomyopathy, reduce the need for scoliosis surgery, and increase survival.", "exact_answer": [["Prednisone"], ["Deflazacort"]], "type": "list", "id": "64414bdb57b1c7a315000058", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Prednisone and deflazacort in Duchenne muscular dystrophy: ", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35713895", "endSection": "title"}, {"offsetInBeginSection": 652, "offsetInEndSection": 766, "text": "Prednisone and deflazacort are steroids that help to reduce muscle inflammation and are used as treatments for DMD", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35713895", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 354, "text": "Deflazacort and prednisone/prednisolone are the current standard of care for patients with Duchenne muscular dystrophy (DMD) based on evidence that they improve muscle strength, improve timed motor function, delay loss of ambulation, improve pulmonary function, reduce the need for scoliosis surgery, delay onset of cardiomyopathy, and increase survival.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35723111", "endSection": "abstract"}, {"offsetInBeginSection": 444, "offsetInEndSection": 680, "text": "This analysis considered patients from the UK NorthStar database (2003-2020) on one of five regimes: \"GC na\u00efve\", \"deflazacort daily\" (DD), \"deflazacort intermittent\" (DI), \"prednisolone daily\" (PD) and \"prednisolone intermittent\" (PI). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35073949", "endSection": "abstract"}]}, {"body": "What is an Albatross plot used for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28453179"], "ideal_answer": "An Albatross plot is a novel graphical tool used for presenting the results of diversely reported studies in a systematic review. It helps to visually display the effect sizes and confidence intervals of individual studies, allowing for a comprehensive overview of the data and facilitating the interpretation of the overall findings.", "exact_answer": [["An Albatross plot is used for presenting the results of diversely reported studies in a systematic review."]], "type": "factoid", "id": "65f37997c4010b4d7800000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "The albatross plot: A novel graphical tool for presenting results of diversely reported studies in a systematic review.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28453179", "endSection": "title"}]}, {"body": "What is the vector for coxiella burnetii transmission?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/37387368", "http://www.ncbi.nlm.nih.gov/pubmed/35190334", "http://www.ncbi.nlm.nih.gov/pubmed/37866329"], "ideal_answer": "The vector for Coxiella burnetii transmission is ticks.", "exact_answer": [["Ticks"]], "type": "factoid", "id": "65f039fdc4010b4d78000002", "snippets": [{"offsetInBeginSection": 334, "offsetInEndSection": 484, "text": "transmitted by ticks include bacteria of the genus Borrelia and the species Francisella tularensis, Anaplasma phagophytophilum and Coxiella burnetii; ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37387368", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Prevalence of Coxiella-infections in ticks - review and meta-analysis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35190334", "endSection": "title"}, {"offsetInBeginSection": 238, "offsetInEndSection": 394, "text": "Excretion of C. burnetii in tick feces and saliva is well documented but the role of these findings or the epidemiological context is discussed controversia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35190334", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "Exploring the diversity of tick-borne pathogens: The case of bacteria (Anaplasma, Rickettsia, Coxiella and Borrelia) protozoa (Babesia and Theileria) and viruses (Orthonairovirus, tick-borne encephalitis virus and louping ill virus) in the European continent.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37866329", "endSection": "title"}]}, {"body": "Can valproate be used during pregnancy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36433783", "http://www.ncbi.nlm.nih.gov/pubmed/36287388", "http://www.ncbi.nlm.nih.gov/pubmed/36401747", "http://www.ncbi.nlm.nih.gov/pubmed/37485793", "http://www.ncbi.nlm.nih.gov/pubmed/37294532", "http://www.ncbi.nlm.nih.gov/pubmed/36828241", "http://www.ncbi.nlm.nih.gov/pubmed/37684052", "http://www.ncbi.nlm.nih.gov/pubmed/38061552"], "ideal_answer": "Valproate should generally be avoided during pregnancy due to the increased risk of malformations and neurodevelopmental disorders in the offspring. Prenatal exposure to valproate has been associated with a higher risk of major congenital malformations, including nervous system, cardiac, oral clefts, clubfoot, and hypospadias. Lower doses of valproate may mitigate the risks, but it is still recommended to consider alternative medications with a lower risk profile for pregnant women.", "exact_answer": "no", "type": "yesno", "id": "65d12b451930410b13000031", "snippets": [{"offsetInBeginSection": 1038, "offsetInEndSection": 1279, "text": "Compared to lamotrigine, there was an increased risk of malformations associated with valproate (n\u00a0=\u00a02,031, aRR\u00a0=\u00a02.05, 95% CI\u00a0=\u00a01.70-2.46) and topiramate (n\u00a0=\u00a0509, aRR\u00a0=\u00a01.81, 95% CI\u00a0=\u00a01.26-2.60), which increased in a dose-dependent manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36433783", "endSection": "abstract"}, {"offsetInBeginSection": 1509, "offsetInEndSection": 1860, "text": "Valproate was associated with several malformation subtypes, including nervous system, cardiac, oral clefts, clubfoot, and hypospadias, whereas lamotrigine and carbamazepine were not.INTERPRETATION: Topiramate is associated with an increased risk of MCM similar to that associated with valproate, but lower doses may mitigate the risks for both drugs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36433783", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "INTRODUCTION: Prenatal exposure to valproate and related substances is associated with a risk of malformations and/or neurodevelopmental disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36287388", "endSection": "abstract"}, {"offsetInBeginSection": 1647, "offsetInEndSection": 1793, "text": "Increased awareness and compliance among healthcare professionals regarding risk minimization measures could limit prenatal exposure to valproate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36287388", "endSection": "abstract"}, {"offsetInBeginSection": 1792, "offsetInEndSection": 1947, "text": "CONCLUSIONS: Our proof-of-concept analysis based on GePaRD showed a strong association between intrauterine exposure to VPA and occurrence of spina bifida.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401747", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Proposal for reference values for the developmental effects of valproate based on human data using a benchmark dose approach.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36828241", "endSection": "title"}, {"offsetInBeginSection": 439, "offsetInEndSection": 598, "text": "Major congenital malformations (MCMs) in offsprings of mothers exposed to valproate during pregnancy have been reported in international scientific literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36828241", "endSection": "abstract"}, {"offsetInBeginSection": 739, "offsetInEndSection": 1112, "text": "Valproate, in monotherapy and polytherapy, has been associated with elevated risk of major congenital malformations and neurodevelopmental disorders in children born to mothers who took it. Topiramate and phenobarbital are also associated with elevated risks of congenital malformations and neurodevelopmental disorders, though the risks are lower than those of valproate. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/37684052", "endSection": "abstract"}]}, {"body": "What are common side effects of the progesterone-only pill (POP)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32538188", "http://www.ncbi.nlm.nih.gov/pubmed/31321765"], "ideal_answer": "Common side effects of the progesterone-only pill (POP) include unscheduled intracyclic bleeding, spotting, poor cycle control, and hyperkalemia.", "exact_answer": [["Irregular menstrual bleeding"], ["Spotting"], ["Poor cycle control"], ["Hyperkalemia"]], "type": "list", "id": "65f847c5c4010b4d78000046", "snippets": [{"offsetInBeginSection": 25, "offsetInEndSection": 144, "text": "progestin-only pills (POPs) is still relatively infrequent, mainly for their unpredictable effect on menstrual bleeding", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32538188", "endSection": "abstract"}, {"offsetInBeginSection": 994, "offsetInEndSection": 1026, "text": "unscheduled intracyclic bleeding", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32538188", "endSection": "abstract"}, {"offsetInBeginSection": 1027, "offsetInEndSection": 1035, "text": "spotting", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32538188", "endSection": "abstract"}, {"offsetInBeginSection": 354, "offsetInEndSection": 373, "text": " poor cycle control", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31321765", "endSection": "abstract"}, {"offsetInBeginSection": 1600, "offsetInEndSection": 1613, "text": "hyperkalemia ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31321765", "endSection": "abstract"}]}, {"body": "What is Primary Diffuse Meningeal Melanomatosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35166475", "http://www.ncbi.nlm.nih.gov/pubmed/32004738", "http://www.ncbi.nlm.nih.gov/pubmed/31690266", "http://www.ncbi.nlm.nih.gov/pubmed/20220448", "http://www.ncbi.nlm.nih.gov/pubmed/12533338", "http://www.ncbi.nlm.nih.gov/pubmed/17330185", "http://www.ncbi.nlm.nih.gov/pubmed/36412389"], "ideal_answer": "Primary Diffuse Meningeal Melanomatosis (PDMM) is a rare form of meningeal melanoma that originates from melanocytes in the leptomeninges. It is characterized by diffusely invasive lesions of the pia mater without signs of extracranial metastases. PDMM can clinically mimic other conditions and is challenging to diagnose due to nonspecific clinical symptoms and radiologic findings.", "type": "summary", "id": "65d129621930410b1300002e", "snippets": [{"offsetInBeginSection": 158, "offsetInEndSection": 369, "text": "In case of diffusely invasive lesions of the pia mater with a tumor of melanocytic origin (without signs of extracranial metastases), the tumors are classified as primary diffuse meningeal melanomatosis (PDMM). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/35166475", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "BACKGROUND: Primary meningeal melanomatosis is a rare leptomeningeal tumor, and the diagnosis is challenging due to nonspecific clinical symptoms and radiologic findings.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/32004738", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Primary diffuse meningeal melanomatosis - a rare form of meningeal melanoma: case report.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31690266", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "BACKGROUND: Meningeal melanomatosis is a rare type of central nervous system neoplasm (with incidence ranging between 3 and 5%) that develops in the course of malignant melanoma. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/31690266", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 299, "text": "Primary diffuse meningeal melanomatosis can clinically mimic a wide variety of other conditions, including lymphoma, leukemia, neurosarcoidosis, metastatic carcinoma, acute disseminated encephalomyelitis, subacute meningitis, viral encephalitis, and idiopathic hypertrophic cranial pachymeningitis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20220448", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "We report a case of primary diffuse meningeal melanomatosis, a rare variant of primary malignant melanoma of the CNS, in a 68-year-old woman. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12533338", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Melanoma malignum constitutes only 0.1% of central nervous system neoplasms. It can occur either as a solid tumour or as a diffuse meningeal melanomatosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17330185", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "Meningeal melanomatosis is an infrequent tumor originating from the melanocytes in the leptomeninges and one of the recognized primary melanocytic tumors of the central nervous system.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/36412389", "endSection": "abstract"}]}]}
